

Vaccine 2025 Poster Programme

[P1.01]

A qualitative study of social processes, hpv vaccine attitudes, and vaccination behavior among hesitant adopter parents

Pearl McElfish¹, Ramey Moore¹, Rachel Purvis¹, Don Willis^{1*}, Sara Sorrell¹, Simon Lee², Erin Finley³, Kevin Sexton⁴, Shashank Kraleti⁴, C'Asia James¹, ¹University of Arkansas for Medical Sciences - Northwest Regional Campus, USA, ²The University of Kansas School of Medicine, USA, ³The University of Texas Health Science Center at San Antonio, USA, ⁴University of Arkansas for Medical Sciences, USA

[P1.02]

RSV Prophylaxis for Children in Africa: Challenges, Opportunities, and Public Health Strategies

Phillip Chigiya*, Pindile Mafina Mukondiwa, Dawa Health, Zimbabwe

[P1.04]

Extrapulmonary manifestation of Respiratory Syncytial Virus

Zehra Yapicioglu Keskin*, Busra Unal, Kubra Aykac, Yasemin Ozsurekci, Ali Bulent Cengiz, Osman Oguz Demir, Hacettepe University Hospitals, Turkey

[P1.05]

Real world study for Mother-to-Child Transmission of Hepatitis B in Guangdong Province, 2021–2023

Tiancheng Xie^{1*}, Mengyang Su², Min Cai², Tianshuo Zhao³, Xiyu Zhang³, Sihui Zhang³, Mingting Wang³, Qingsong Xu³, Yujie Cheng³, Shuang Gao², Fuqiang Cui³, ¹Peking University, China, ²Department of Maternity Group Health, Guangdong Women and Children Hospital, Guangzhou, China, ³Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China

[P1.06]

Evaluating the potential clinical and economic impact of Clesrovimab for infants in England and Wales

Klodeta Kura^{1*}, Colleen Burgess², Kayla Engelbrecht¹, Ian Matthews¹, Dionysios Ntais¹, Yao-Hsuan Chen¹, ¹Merck Sharp & Dohme UK Ltd, UK, ²Merck & Co Inc, USA

[P1.07]

Childhood Vaccine Hesitancy and Refusal in Türkiye: A Meta-Analysis

Kubra Aykac*, Osman Demir, Yasemin Ozsurekci, Hacettepe University Hospitals, Turkey

[P1.08]

Influenza-Associated Myocarditis in Two Pediatric Cases: A Rare but Severe Complication

Ceren Yilmaz*, Kubra Aykac, Yasemin Ozsurekci, Hacettepe University Hospitals, Turkey

[P1.09]

Ten Years of HPV Vaccination in Brazil: An Analysis of the First Campaign Conducted in the Capital of Brazil

Talita Rodrigues Gomes^{1*}, Maíra Catharina Ramos², ¹UniCesumar, Brazil, ²University of Brasilia, Brazil

[P1.10]

Vaccination trends in children under 1 year of age in Latin America: an analysis from 2001 to 2030

Maíra Catharina Ramos^{1*}, Talita Rodrigues Gomes², ¹University of Brasilia, Brazil, ²UniCesumar, Brazil

[P1.11]

The improvement of adaptive immune responses towards COVID-19 following Diphtheria–Tetanus–Pertussis and SARS-CoV-2 vaccinations in Indonesian children: exploring the roles of heterologous immunity.

Theresia Santi^{1*}, Juandy Jo^{2,3}, Badriul Hegar^{4,5}, Sri Rezeki S Hadinegoro⁴, ¹Faculty of Medicine, President University, Indonesia, ²Department of Biology, Faculty of Health Sciences, Universitas Pelita Harapan, Indonesia, ³Mochtar Riady Institute for Nanotechnology, Indonesia, ⁴Department of Child Health, Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia, Indonesia, ⁵Indonesian Medical Education and Research Institute, Faculty of Medicine, Universitas Indonesia, Indonesia

[P1.12]

AVA– study protocol for an AI-supported vaccination assistant to improve vaccination rates in patients with mild cognitive impairment in primary care

Linda Sanftenberg^{1*}, Felix Bader¹, Tobias Bundschuh¹, Max Lang², Quirin Würschinger³, Frauke Kreuter³, Jochen Gensichen¹, ¹Institute of General Practice and Family Medicine, LMU University Hospital, LMU Munich, Munich, Germany, ²Department of Population Health and Statistics, University of Oxford, Oxford, UK, ³Department of Statistics, Ludwig-Maximilians-University Munich, Munich, Germany

[P1.13]

Unraveling the Physical Adjuvant Effect of High-Density Microarray Patches Through Spatial Multi-Omics

Christopher McMillan¹, Jovin Choo², Danushka Wijesundara^{2,3}, David Muller², ¹The University of Queensland School of Chemistry and Molecular Biosciences, Australia,²The University of Queensland School of Chemistry and Molecular Biosciences, Australia,³Vaxxas Pty Ltd, Australia

[P1.14]

Nasal administration of the novel RSPVac mucosal vaccine protects mice from lethal H5N1 clade 2.3.4.4b infection
Joy-Yan Lam*, Kin-Hang Kok, The University of Hong Kong, Hong Kong

[P1.15]

Defining conserved sites of vulnerability on the influenza B HA using human monoclonal antibodies
Yee-Chen Liu¹, Yi Liu^{2,3}, Andrew Kelly¹, Robyn Esterbauer¹, Stephen Kent^{1,4}, Marios Koutsakos¹, Adam Wheatley¹,
¹Department of Microbiology and Immunology, University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia,²Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Australia,³WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia,⁴Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria, Australia

[P1.16]

Comparison of the efficacy of whole particle influenza virus vaccine and split vaccine in dexamethasone-treated mice
Hirohito Ishigaki*, Shiga University of Medical Science, Japan

[P1.17]

Comparing methods collecting mucosal secretions and detecting SARS-CoV-2 spike IgA in three laboratories across three countries

Katherina Aguilera¹, Oscar Bladh¹, Salma Sheikh-Mohamed², Jessica Nardulli^{3,4}, Disha Bhavsra^{3,4}, Dylan Fitzgerald^{3,4}, Gagandeep Singh^{3,4}, Lesley Ward², Giulio Kleiner^{3,4}, Gary Chao², Nina Greilert Norin¹, Tamas Pongracz¹, Charles Gleason^{3,4}, Matilda Berkel⁵, Mikael Åberg⁶, Florian Krammer^{3,4,7,8}, Jen Gommerman², Charlotte Thålin¹, Viviana Simon^{3,4,7,9,10}, ¹Karolinska Institute Department of Clinical Sciences Danderyd Hospital, Sweden,²University of Toronto Department of Immunology, Canada,³Icahn School of Medicine at Mount Sinai Department of Microbiology, USA,⁴Center for Vaccine Research and Pandemic Preparedness (C-VarPP), Icahn School of Medicine at Mount Sinai, New York, USA,⁵Dept of Plant Physiology, National Bioinformatics Infrastructure Sweden, Sweden,⁶SciLifeLab, Sweden,⁷Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, USA,⁸Ignaz Semmelweis Institute, Interuniversity Institute for Infection Research, Medical University of Vienna, Austria,⁹Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, USA,¹⁰The Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, USA

[P1.18]

Differences in virus composition and diversity associate with severity in adult pneumonia patients in Singapore
Peter Cronin¹, Jiayi Li¹, Foong Ying Wong¹, Dongqiang Cheng¹, Jenny Low^{1,2}, Tsin Yeo³, Paul Tambayah⁴, Gavin Smith¹, Yvonne Su¹, ¹Duke-NUS Medical School, Singapore,²Singapore General Hospital Department of Infectious Diseases, Singapore,³Woolands General Hospital, Singapore,⁴Department of Medicine, National University Hospital, Singapore

[P1.19]

Immunogenicity of the monovalent omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine in people living with HIV (PLWH)

Maxim Cherneha¹, Isabel Zydek¹, Peer Braß¹, Johannes Korth², Sarah Jansen¹, Stefan Esser³, Christina Karsten³, Folker Meyer⁴, Ivana Kraiselburd⁴, Ulf Dittmer⁵, Monika Lindemann⁶, Peter Horn⁶, Oliver Witzke¹, Laura Thümmeler^{1,6}, Adalbert Krawczyk^{1,5}, ¹Department of Infectious Diseases, West German Centre of Infectious Diseases, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, Germany,²Department of Nephrology, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, Germany,³Institute for the Research on HIV and AIDS-Associated Diseases, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, Germany,⁴Institute for Artificial Intelligence in Medicine, University Hospital Essen, University Duisburg-Essen, Germany,⁵Institute for Virology, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, Germany,⁶Institute for Transfusion Medicine, University Medicine Essen, University Hospital Essen, University Duisburg-Essen, Germany

[P1.20]

From genomics to therapeutics: unravelling the evolution of human parainfluenza viruses and their implications for monoclonal antibody strategies

Bo Wang, Dongqiang Cheng, Xiang Li, Jia Yi, Peter Cronin, Giselle Ng, Satoru Watanabe, Gavin Smith, Yvonne Su*, Duke-NUS Medical School, Singapore

[P1.21]

Production and characterisation of antigenically stable enterovirus A71 genotype C4 VLPs in *Pichia pastoris*.
Nawani Tanapatkunnathorn*, Francesca Goldfinch, Natalie Kingston, David Rowlands, Nicola Stonehouse, University of Leeds, UK

[P1.22]

Real-world effectiveness of recombinant herpes zoster vaccine: A retrospective, cohort study in Japan

Satoko Ohfuji^{1,2}, Nozomu Toyama³, Kyoko Kondo⁴, Hisao Muto⁵, Wakaba Fukushima^{1,2,6}, ¹Department of Public Health, Osaka Metropolitan University Graduate School of Medicine, Japan, ²Research Center for Infectious Disease Sciences, Osaka Metropolitan University Graduate School of Medicine, Japan, ³Toyama Dermatologic Clinic, Japan, ⁴OMU Core Facilities Life Sciences Section, Osaka Metropolitan University, Japan, ⁵Kusuri no Aoki Co., Ltd., Japan, ⁶Osaka International Research Center for Infectious Diseases, Osaka Metropolitan University, Japan

[P1.23]

Strategies to develop effective and safe mRNA-based therapeutics

Akiko Yanagiya*, Rena Akahori, Miki Masai, Tomohiro Sawadaishi, Aoi Onuma, Hiroaki Murakami, Yanwen Feng, Hayato Sato, Naoki Matsumoto, Tetsuo Yoshida, Kazuyuki Nakashima, ARCALIS, Inc., Japan

[P1.24]

Haemophilus Influenzae Carriage during the COVID-19 Pandemic and the Emergence of New Serotypes

Kubra Aykac¹, Gokhan Guvenkaya², Osman Oguz Demir¹, Ozgen Eser³, Alpaslan Alp³, Sevilay Karahan⁴, Ali Bulent Cengiz¹, Yasemin Ozsurekci¹, ¹Hacettepe University Faculty of Medicine, Department of Pediatric Infectious Diseases, Ankara, Turkey, ²Hacettepe University Faculty of Medicine, Department of Pediatrics, Ankara, Turkey, ³Hacettepe University Faculty of Medicine, Department of Medical Microbiology, Ankara, Turkey, ⁴Hacettepe University Faculty of Medicine, Department of Biostatistics, Ankara, Turkey

[P1.25]

From Recommendation to Results: A Decade of Adult PCV13 Vaccination in the U.S.

Jeffrey Vietri¹, Euan Dawson², Paula Peyrani¹, Mark H. Rozenbaum³, ¹Pfizer Inc, USA, ²Pfizer Inc, UK, ³Pfizer Inc, The Netherlands

[P1.26]

The MyVax Study: what are the preferred products and implementation strategies of multiple vaccines in pregnancy?

Michelle Giles^{1,2}, Cathrin Makdsi^{2,1}, Sushena Krishnaswamy^{2,1}, Naomi Whyler¹, Lisa LeBec¹, Daniel Rolnik^{1,2}, ¹Monash University, Australia, ²Monash Health, Australia

[P1.27]

Bioinspired Lipid Vaccine Delivery System Overcoming Mucosal Barrier for Respiratory Syncytial Virus Vaccine

Bingbing Sun*, Yiyang Guo, Zhili Wang, Dalian University of Technology, China

[P1.28]

Variant-specific IgA protects against Omicron infection - estimating protection durations against SARS-CoV-2 infection

Pei Xiang Hor¹, Luis Ponce², Yuqian Wang², Ananya Singh², Chiew Yee Loh¹, Siew Wai Fong¹, Lisa Ng¹, Laurent Renia¹, Keisuke Ejima², Yun Shan Goh¹, ¹A*STAR Research Entities, Singapore, ²Lee Kong Chian School of Medicine, Singapore

[P1.29]

Revisiting the FDA Toxicity Grading Scale for Healthy Adults: A Simulation Study on the Risks of Overestimation and Misclassification in Vaccine Safety Assessment

Masanori Nojima¹, Fumitaka Nagamura¹, Yoshikazu Yuki², Hiroshi Kiyono³, ¹The Institute of Medical Science, The University of Tokyo, Japan, ²Department of Human Mucosal Vaccinology, Chiba University Hospital, Japan, ³Chiba University Synergy Institute for Futuristic Mucosal Vaccine Research and Development (cSIMVa), Future Medicine Education and Research Organization, Chiba University, Japan

[P1.30]

Beyond antigen design: Harnessing adjuvants to advance universal influenza virus vaccines

Irene González-Domínguez¹, Adam Abdeljawad¹, Marta Boza¹, William Shea¹, Tsoi Ying Lai¹, Nicholas Lemus¹, Mitali Mishra¹, Gabriel Laghlai^{1,2,3}, Eduard Puente-Massaguer^{1,4}, Disha Atulkumar Bhavsar¹, Joshua Yueh¹, Jose Martínez-Guevara¹, Michael Schotsaert^{1,2,5,6}, Florian Krammer^{1,7,4,8}, Peter Palese^{9,1}, Weina Sun¹, ¹Icahn School of Medicine at Mount Sinai Department of Microbiology, USA, ²Icahn School of Medicine at Mount Sinai Health and Emerging Pathogens Institute, USA, ³Ghent University, Belgium, ⁴Icahn School of Medicine at Mount Sinai Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), USA, ⁵Icahn School of Medicine at Mount Sinai Icahn Genomics Institute, USA, ⁶Icahn School of Medicine at Mount Sinai and Jennifer Lipschultz Precision Immunology Institute, USA, ⁷Icahn School of Medicine at Mount Sinai Department of Pathology, USA, ⁸Medical University of Vienna, Austria, ⁹Icahn School of Medicine at Mount Sinai, USA

[P1.31]

Development and evaluation of a consensus-based recombinant H7N9 avian influenza vaccine against heterologous challenge in poultry

Mingeun Sagong*, Animal and Plant Quarantine Agency, Republic of Korea

[P1.32]

From Trials to Populations: Translating Efficacy of Short-Acting Prophylactic Vaccines Against Infectious Disease into Public Health Impact

Katherine Turpie¹, Dariya Nikitin², Lilith K Whittles², ¹University College London, UK, ²Imperial College London, UK

[P1.33]

Protective efficacy of commercial avian infectious bronchitis vaccines against Japan-like virus in Taiwan

Yu-Wei Tsai^{*1,2}, Ming-Chu Cheng^{1,2}, ¹Department of Veterinary Medicine, National Pingtung University of Science and Technology, Taiwan, ²Research Center for Animal Biologics, National Pingtung University of Science and Technology, Taiwan

[P1.34]

Cross-protective immunity against SARS-CoV-2 induced by MERS-CoV infection in hDPP4 transgenic mice

Naoko Iwata-Yoshikawa*, Nozomi Shiwa-Sudo, Yusuke Sakai, Tadashi Okamura, Tadaki Suzuki, Noriyo Nagata, Japan Institute for Health Security, Japan

[P1.35]

Efficacy of various replicon-RNA vaccines for Cache Valley virus in multiple murine models

John Muller^{*1}, Jesse Erasmus², Taylor Stone², Manette Tanelus¹, Krisangel Lopez¹, Albert Auguste¹, ¹Virginia Polytechnic Institute and State University, USA, ²HDT Bio Inc, USA

[P1.36]

COVID-19 Booster Uptake Among Older Adults in Hong Kong: Policy Impact and Barriers for Underprivileged Populations

Siu-Chee Sophia Chan*, Wan-Jia Aaron He, Hoi-Yan Ferrina Cheung, Yuna Shao, Tsz-Yin Wong, The University of Hong Kong Li Ka Shing Faculty of Medicine School of Public Health, Hong Kong

[P1.37]

Inactivated H5N1 Vaccine Induces Cross-clades protective Immune Responses in a Ferret Model

Yi-An Ko*, I-Ting Wu, Ying-Hsiu Wang, Wen-Chun Liu, Infectious Disease Core Facility, Biomedical Translation Research Center, Academia Sinica, Taiwan

[P1.38]

Maternal Antibody Transfer Provides Neonatal Protection and Supports Safe Development of Pneumococcal Immunity via PspA Antibody-Mediated Protection Against Initial Infection

Takafumi Noguchi^{*1,2}, Hidehiko Suzuki^{3,2}, Mayuko Yamawaki², Takeshi Sugimoto^{3,2}, Yuka Koizumi², Kazue Utsumi², Paola Miyazato^{3,2}, Eiji Morita⁴, Hirota Ebina^{1,2,5,6,7}, ¹Virus Vaccine Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Institute for Open and Transdisciplinary Research Initiatives, The University of Osaka, Japan, ²The Research Foundation for Microbial Diseases of Osaka University (BIKEN), Japan, ³Virus Vaccine Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Institute for Open and Transdisciplinary Research Initiatives, The University of Osaka, Japan, ⁴Department of Biochemistry and Molecular Biology, Faculty of Agriculture and Life Science, Hirosaki University, Japan, ⁵Center for Advanced Modalities and DDS (CAMaD), The University of Osaka, Suita, Japan, ⁶Research institute for Microbial Diseases, The University of Osaka, Japan, ⁷Center for Infectious Disease Education and Research (CiDER), The University of Osaka, Japan

[P1.39]

Adenoviral vector encoding neuraminidase from avian H5N1 influenza A virus elicits broadly cross-reactive cellular and humoral immune responses following prime immunization

Cosette Schneider^{*1}, Juliaha Hayes¹, Katherine McIntire¹, Aisha Souquette¹, Alesandra Rodriguez², Jason Germain², Andrew Ward², Julianna Han², Lynda Coughlan^{1,3}, ¹University of Maryland Baltimore Department of Microbiology & Immunology, USA, ²The Scripps Research Institute, USA, ³University of Maryland Baltimore Center for Vaccine Development & Global Health, USA

[P1.40]

A Multi-Country Comparison of Number Needed to Vaccinate for PCV15 and PCV20 in Infants

Mark Rozenbaum^{*1}, Euan Dawson², Ayman Sabra³, Maria J Tort⁴, An Ta⁵, Susannah Sadler⁵, ¹Pfizer Inc. Capelle a/d IJssel, The Netherlands, ²Pfizer Inc. Tadworth, KT20 7NY, UK, ³Pfizer Inc., Paris, France, ⁴Pfizer Inc., Collegeville, PA, USA, ⁵Cytel Inc. London, UK

[P1.41]

Preparing for future Group B Streptococcus vaccines: Attitudes of pregnant women in Australia

Prabha Andraweera^{*1,2}, Bing Wang^{1,2}, Emma Jeffs², Mark McMillan^{1,3}, Helen Marshall^{2,1}, ¹The University of Adelaide Adelaide Medical School, Australia, ²Women's and Children's Hospital Adelaide, Australia, ³Women's and Children's Hospital Adelaide, Australia

[P1.42]

Randomised controlled trial of behavioural nudges delivered through text messages to increase influenza and COVID-19 vaccine uptake among pregnant women (EPIC Study) in Australia

Prabha Andraweera^{*1,2}, Bing Wang^{1,2}, Margie Danchin^{3,4}, Christopher Blyth^{5,6}, Ivo Vlaev⁷, Jason Ong⁸, Jodie Dodd^{1,2}, Jennifer Couper^{1,2}, Thomas Sullivan^{9,10}, Alana Alana⁹, Jonathan Karnon¹¹, Nicola Spurrier¹², Michael Cusack¹², Dylan Mordaunt¹¹, Dimi Simatos¹³, Gus Dekker^{1,13}, Samantha Carlson⁶, Jane Tuckerman^{4,14}, Nicholas Wood^{15,16}, Lisa Whop¹⁷, Joanne Koch¹³, Kirsty Herewane², Deborah Pidd¹⁸, Ashleigh Rak^{4,3}, Helen Marshall^{1,2}, ¹The University of Adelaide Adelaide Medical School, Australia, ²Women's and Children's Hospital Adelaide, Australia, ³The Royal Children's Hospital, Melbourne, Victoria, Australia, ⁴The University of Melbourne, Australia, ⁵Perth Children's Hospital, Perth, Western Australia, Australia, ⁶The University of Western Australia, Australia, ⁷University of Warwick Business School, UK, ⁸Monash University, Australia, ⁹South Australian Health and Medical Research Institute Limited, Australia, ¹⁰The University of Adelaide,

Australia,¹¹Flinders University, Australia,¹²SA Health, Australia,¹³Lyell McEwin Hospital, Australia,¹⁴Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Australia,¹⁵The University of Sydney, Australia,¹⁶Children's Hospital Westmead, Sydney, New South Wales, Australia,¹⁷Australian National University, Australia,¹⁸Mercy Hospital, Melbourne, Australia

[P1.43]

A role for antibodies in preventing severe outcomes from COVID-19

Karen Elias¹, Ainslie Mitchell¹, Eva Stadler¹, Timothy Schlub^{1,2}, Shanchita Khan¹, Stephen Kent^{3,4,5}, Deborah Cromer¹, Miles Davenport¹, David Houry¹, ¹The Kirby Institute, Australia,²The University of Sydney School of Public Health, Australia,³The University of Melbourne Department of Microbiology and Immunology, Australia,⁴The Peter Doherty Institute for Infection and Immunity, Australia,⁵Melbourne Sexual Health Centre, Australia

[P1.44]

Respiratory syncytial virus (RSV) post-F IgG response and hospitalization duration: implications for prognosis and immunization efficacy.

Anthony Simbeya^{1,2}, Manami Negoro¹, Elijah Kuurdor^{3,1}, Ken Sugata¹, Mizuho Nagao¹, Shigeru Suga¹, Kiyosu Taniguchi¹, ¹National Mie Hospital, Japan,²Mie University Graduate School of Medicine Faculty of Medicine, Japan,³Mie University, Japan

[P1.45]

Determinants of Compliance With the Two-Dose Recombinant Zoster Vaccine Series Among Older Adults: A Cross-Sectional Study From a Primary Health Care Center in Saudi Arabia

Adam Aldhawyan¹, Marwa shafey¹, Renad Alrasan², Sarah Alsubaie², Sarah Alosaimi², Byader Alabdullah², Elaf Bajameel², Maiyada Aldossary², Reham Alshablan², Esra Alkhader², ¹Family and Community Medicine Department, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia,²Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia, Saudi Arabia

[P1.46]

Safety and efficacy of a quadrivalent inactivated vaccine against *Glaesserella parasuis* serovar 5

Yu-An Tai^{1,2,3}, Chia-Hung Yen^{1,2,3}, Yi-Cheng Li^{1,2}, Hsuan-Po Chen^{1,2}, Ni-Jyun Ke¹, Chiung-I Huang¹, Chao-Nan Lin^{1,2,3}, Ming-Tang Chiou^{1,2,3}, Wei-Hao Lin^{1,2,3}, ¹Department of Veterinary Medicine, National Pingtung University of Science and Technology, Taiwan,²Animal Disease Diagnostic Center, National Pingtung University of Science and Technology, Taiwan,³Sustainable Swine Research Center, National Pingtung University of Science and Technology, Taiwan

[P1.47]

Transient increased risk of shingles post Shingrix vaccination: A brief risk bump on long road of protection

Aishwarya N Shetty^{1,2}, Daneeta Hennessy^{1,2}, Gonzalo Sepulveda Kattan^{1,2}, Samar Ojaimi^{3,4}, Jim P Buttery^{1,2,5,6}, Hazel J Clothier^{1,2,5}, ¹Epidemiology Informatics, Centre for Health Analytics, Melbourne Children's Campus, Melbourne, Australia,²SAEFVIC, Murdoch Children's Research Institute, Melbourne, Australia,³Monash Pathology, Monash Health, Clayton, Australia,⁴Department of Medicine, Monash University, Clayton, Australia,⁵Department of Paediatrics, University of Melbourne, Melbourne, Australia,⁶The Royal Children's Hospital, Melbourne, Australia

[P1.48]

Protective efficacy of a non-replicative, attenuated vaccinia virus DIs strain against mpox virus infection in mice.

Fumihiko Yasui¹, Ahmad Faisal Amiry¹, Koji Ishii², Michinori Kohara¹, ¹Tokyo Metropolitan Institute of Medical Science, Japan,²National Institute of Infectious Diseases, Japan

[P1.49]

Integrin Expression Patterns of Human Cell Lines under Homeostatic and Inflammatory Conditions

Martina Bardino Mørch*, Jeanne Toft Jakobsen, Gitte Erbs, Gregers Jungersen, Department of Infectious Disease Immunology, Center for Vaccine Research, Statens Serum Institut, Copenhagen, Denmark

[P1.50]

Developing an adenovirus vector-based vaccine against *Staphylococcus aureus*

Rachel Lapeyre*, Anne Moore, University College Cork, Ireland

[P1.51]

Induction of influenza-specific immunity in pigs using dissolvable microneedle patches to deliver an adenovirus-based vaccine

Inés C6-Rives*, Katherine Acevedo¹, Imane Allaoui¹, Kayan Tam², Emery G Dora², Grace Copithorne³, Edgar Garcia Manzanilla³, Kelly A S da Costa⁴, Nigel J Temperton⁴, Sean N Tucker², Ann Ying-An Chen¹, Anne C Moore¹, ¹University College Cork, Ireland,²Vaxart Inc, USA,³The Teagasc Pig Development Department, Ireland,⁴Viral Pseudotype Unit, Medway School of Pharmacy, UK

[P1.52]

Real-world effectiveness of COVID-19 vaccines in people with secondary immunodeficiency

Shanchita Khan*, Eva Stadler, Karen Elias, Deborah Cromer, Chansavath Phetsouphanh, Priyanka Hastak, Rehana Hewavisenti, Ruchika Joshi, Miles Davenport, Sarah Sasson, David Houry, The Kirby Institute, Australia

[P1.53]

Nudging toward COVID-19 and influenza vaccination in children with medically at-risk conditions

Bing Wang^{*1,2}, Prabha Andraweera^{1,2}, Margie Danchin^{3,4}, Christopher Blyth^{5,6}, Ivo Vlaev⁷, Jason Ong⁸, Jodie Dodd^{9,1}, Jennifer Couper^{1,2}, Thomas Sullivan¹⁰, Alana Cuthbert¹⁰, Ashleigh Rak⁴, Kirsty Herewane⁹, Louisa Paparo¹¹, Jonathan Karnon¹², Nicola Spurrier¹³, Michael Cusack¹³, Dylan Mordaunt¹², Dimi Simatos¹⁴, Gus Dekker¹⁴, Samantha Carlson⁵, Jane Tuckerman^{15,4}, Nicholas Wood^{16,17}, Lisa Whop¹⁸, Helen Marshall^{1,2}, ¹The University of Adelaide, Australia, ²Women's and Children's Health Network, Australia, ³The Royal Children's Hospital, Melbourne, Australia, ⁴Murdoch Children's Research Institute, Australia, ⁵The University of Western Australia, Australia, ⁶Wesfarmers Centre of Vaccines and Infectious Diseases, Australia, ⁷University of Warwick, UK, ⁸Monash University, Australia, ⁹Women's and Children's Hospital, Adelaide, Australia, ¹⁰South Australian Health and Medical Research Institute Limited, Australia, ¹¹Perth Children's Hospital, Australia, ¹²Flinders University, Australia, ¹³SA Health, Australia, ¹⁴Lyell McEwin Hospital, Australia, ¹⁵The University of Melbourne, Australia, ¹⁶Children's Hospital Westmead, Australia, ¹⁷The University of Sydney, Australia, ¹⁸Australian National University, Australia

[P1.54]

Development and Validation of a Free Polysaccharide Separation Method for Quadrivalent Meningococcal Conjugate Vaccines

Yoon-Sil Yang^{*}, Ji-Yun Seo, So Yeong Kwon, Hanbit Bong, Won Gyo Jang, Suk-Bae LEE, Gi Hyun Kim, Kyung Hee Sohn, National Institute of Food and Drug Safety Evaluation, Republic of Korea

[P1.55]

Seroprevalence of Measles, Rubella, Varicella-Zoster, and Mumps IgG Antibodies in Immunocompromised Patients with Hematologic Diseases and HIV Infection: Real-World Data from a Single Center in Japan

Michiko Koga^{*1,2}, Akari Fukuda², Kazuaki Yokoyama², Hiroshi Yotsuyanagi², ¹The University of Tokyo Pandemic Preparedness Infection and Advanced Research Center (UTOPIA), Japan, ²The University of Tokyo Institute of Medical Science, Japan

[P1.56]

A SARS-CoV-2 LP.8.1-targeted unmodified mRNA vaccine eliciting enhanced cross-neutralization against emerging SARS-CoV-2 variants

Jieun Kim^{*}, Seo-Yeon Hwang¹, Han Young Seo¹, Jong-Won Oh^{1,2}, ¹Department of Biotechnology, Yonsei University, Seoul 03722, Korea, Republic of Korea, ²RpexBio Inc., Yonsei University Engineering Park B140, Seoul 03722, Korea, Republic of Korea

[P1.57]

K3-SPG-mediated long-term protection against viral infection

Asuka Joy Tobuse^{*}, Kouji Kobiyama^{1,2}, Jun Tsuchida³, Teppei Hara³, Masamitsu Asaka⁴, Daichi Utsumi⁴, Yaeko Nakajima-Takagi⁵, Motohiko Oshima⁵, Tomoya Hayashi³, Burcu Temizoz³, Hideo Negishi³, Yasuhiro Yasutomi⁴, Atsushi Iwama⁵, Ken J Ishii^{3,2}, ¹Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, Japan, ²International Vaccine Design Center (IMSUT), Japan, ³Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, Japan, ⁴Laboratory of Immunoregulation and Vaccine Research, Tsukuba Primate Research Center, National Institutes of Biomedical Innovation, Health and Nutrition, Japan, ⁵Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, University of Tokyo, Japan

[P1.58]

Decoding longitudinal antibody and Fc-effector functions against SARS-CoV-2 variants

Felicia Hwa^{*1}, Carolyn A Cohen², Prathanporn Kaewpreedee², Carissa Aurelia¹, Amy Chung¹, Nancy HK Leung³, Benjamin J Cowling³, David SC Hui⁴, Malik JS Peiris², Sophie A Valkenburg¹, ¹The Peter Doherty Institute for Infection and Immunity, Australia, ²HKU-Pasteur Research Pole, Hong Kong, ³WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, University of Hong Kong, Hong Kong, ⁴Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong

[P1.59]

Comparative Analysis of Prefusion and Postfusion F Protein Antibody Responses in RSV Infection Across Multiple Years

Elijah Deku-Mwin Kuurdor^{*1,2}, Manami Negoro², Jennifer Xolali Amexo³, Ken Sugata², Prince Baffour Tonto^{4,5}, Anthony Simbeya², Junpei Ohtsuka^{6,7}, Soh Yamamoto⁸, Noriko Ogasawara⁹, Masayuki Fukumura^{6,7}, Tetsuya Nosaka⁶, Hajime Kamiya¹, Kiyosu Taniguchi², ¹Department of Public Health, Occupational Health and Applied Epidemiology, Mie University Graduate School of Medicine, Japan, ²National Hospital Organization, Mie National Hospital, Japan, ³Department of Epidemiology and Biostatistics, University of Health and Allied Science, Ghana, ⁴Rutgers Global Health Institute, Rutgers University, USA, ⁵Department of Medicine, Division of Allergy, Immunology, and Infectious Disease

and Child Health Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, USA,⁶Department of Microbiology and Molecular Genetics, Mie University Graduate School of Medicine, Japan,⁷BioComo Inc., Japan,⁸Department of Infectious Diseases, Division of Microbiology, Sapporo Medical University School of Medicine, Japan,⁹Department of Microbiology, Sapporo Medical University School of Medicine, Japan

[P1.60]

A novel multi-epitope vaccine candidate against foot-and-mouth disease virus serotypes

Jong-Soo Lee^{*1}, Jong-Hyeon Park², ¹College of Veterinary Medicine, Chungnam National University, Republic of Korea,²Animal and Plant Quarantine Agency, Republic of Korea

[P1.61]

Chemical engineering of polyplexes for improved messenger RNA therapeutic delivery and expression

Fadlina Aulia^{*1}, Qiao Nan¹, Mao Hori², Kaori Taniwaki¹, Naoki Yamada¹, Mitsuru Naito³, Hyun Jin Kim⁴, Satoshi Uchida⁵, Kanjiro Miyata¹, ¹The University of Tokyo, Department of Materials Engineering, Japan,²Institute of Science Tokyo, Department of Organic Biomaterials, Japan,³Tokyo University of Science - Katsushika Campus, Japan,⁴Inha University Department of Biological Engineering, Republic of Korea,⁵Institute of Science Tokyo, Department of Advanced Nanomedical Engineering, Japan

[P1.62]

Outer Membrane Vesicles from Detoxified Salmonella Gallinarum Vaccine Strains Exhibit Potential as Mucosal Adjuvants for Influenza Vaccines

Ho-Won Kim^{*1}, Sun-Min Ahn², Jin-Ha Song¹, Seung-Eun Son¹, Seung-Ji Kim¹, Jin-Mi Park¹, Gwang-Muk Lim³, Ga-Hye Kim³, Seohyeon Jeon³, Seung-Muk Baek³, Jeong-Min Ju³, Sung-Min Koo³, Sun-Young Sunwoo³, Jae-Hoon Kim³, Kang-Seuk Choi^{1,4}, Hyuk-Joon Kwon^{2,5,4,6}, ¹Laboratory of Avian Diseases, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea,²Laboratory of Poultry Medicine, College of Veterinary Medicine, Seoul National University, Pyeongchang, Republic of Korea,³Corporate R&D Center, Green Cross Veterinary Products, Youngin, Republic of Korea,⁴Research Institute for Veterinary Science, College of Veterinary Medicine, Seoul National University, Seoul, Republic of Korea,⁵Farm Animal Clinical Training and Research Center, GBST, Seoul National University, Pyeongchang, Republic of Korea,⁶GeNiner Inc., Seoul, Republic of Korea

[P1.63]

Stalling Protection: A Decade of Regional Declines in Measles Vaccination Coverage in the Philippines

Michelle Ylade^{*}, Kristal An Agrupis, University of the Philippines Manila Institute of Child Health and Human Development, The Philippines

[P1.65]

Low influenza & COVID-19 vaccination coverage among pregnant women in Norway: a population-based study (2023-2024)

Melanie Stecher^{*1}, Hinta Meijerink¹, Jesper Dahl¹, Evy Dvergsdal², Suzanne Campbell², Inger Johanne Brakken³, Hilde Engjom⁴, Margrethe Greve-Isdahl^{1,5}, ¹Department of Infection Control and Vaccines, Norwegian Institute of Public Health, Norway,²Department of Infection Control Registries, Norwegian Institute of Public Health, Oslo, Norway,³Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway,⁴Department of Health Registry Research and Development, Norwegian Institute of Public Health, Bergen, Norway,⁵Faculty of Medicine, University of Oslo, Oslo, Norway

[P1.66]

Developing an anti-MERS-CoV vaccine for Camel

Long-Fung Mak^{*1,2}, Chun-Kit Yuen^{1,2}, Wan-Man Wong^{1,2}, Lok-Yi Cheung^{1,2}, Kin-Hang Kok^{1,2}, ¹The University of Hong Kong, Hong Kong,²Centre for Virology, Vaccinology and Therapeutics, Hong Kong

[P1.67]

Development of a vaccine for Lassa virus infection: from research grade to GMP compliant

Emma Kennedy^{*}, Sarah Webster, Annahita Rajabzabeh, Stephen Findlay-Wilson, Roger Hewson, Stuart Dowall, UK Health Security Agency Porton, UK

[P1.68]

Engineering LNPs for Vaccines: Lipid Design Drives Immune Activation

Preeti Sharma^{*1}, Uri Elia², Uri Sprecher¹, Gonna Somu Naidu¹, Inbal Hazan-Halevy¹, Meir Goldsmith¹, Eleni Samaridou³, Moritz Beck-Broichsitter³, Dan Peer¹, ¹Tel Aviv University The Shmunis School of Biomedicine and Cancer Research, Israel,²Israel Institute for Biological Research, Israel,³Merck KGaA, Germany

[P1.69]

Accelerated attenuation of infectious bronchitis virus via mutation induction using nucleoside analogs.

Dong-Wook Lee*, Da-Won Kim, Ji-Yun Kim, Ye-Jin Lee, Jung-Hoon Kwon, *Kyungpook National University, College of Veterinary Medicine, Laboratory of Veterinary Microbiology, Republic of Korea*

[P1.70]

Testing the immunomodulatory effects of lipid nanoparticles and mRNA of novel vaccines

Katharina Walther¹, Katrin Bagola¹, Verena Roth¹, Jessica Roos¹, Thorsten J. Maier¹, Max Bastian², Ger van Zandbergen^{1,3,4}, ¹*Paul Ehrlich Institute, Germany,* ²*Friedrich-Loeffler-Institute Federal Research Institute for Animal Health, Germany,* ³*University Medical Center of the Johannes Gutenberg University Mainz, Germany,* ⁴*Research Center for Immunotherapy Johannes Gutenberg University Mainz, Germany*

[P1.71]

Analysis of subpopulations in commercial live attenuated infectious bronchitis virus vaccines in South Korea

Ye-Jin Lee*, Da-Won Kim, Ji-Yun Kim, Dong-Wook Lee, Jung-Hoon Kwon*, *Kyungpook national university, college of veterinary medicine, laboratory of, Republic of Korea*

[P1.72]

Cross-Protective Efficacy of GI-19 Lineage Live Vaccine Against a Recombinant GVI-1 Lineage Infectious Bronchitis Virus Isolate from Korean Native Chickens

Da-Won Kim¹, Ji-Yun Kim¹, Dong-Wook Lee¹, Ye-Jin Lee¹, Heesu Lee², Jung-Hoon Kwon¹, ¹*Laboratory of Veterinary Microbiology, College of Veterinary Medicine, Kyungpook National University, Republic of Korea,* ²*Laboratory of Avian Diseases, College of Veterinary Medicine, Konkuk University, Republic of Korea*

[P1.73]

Diphtheria, tetanus, pertussis seropositivity among healthcare workers - a cross-sectional study at the National Centre of Infectious Diseases and Tan Tock Seng Hospital, Singapore

Dwee Wee Lim¹, Jean-Marc CHAVATTE², Andy Jian Hao AU³, Muhammad Zulfikar MOHAMED_ASHAR³, Paul Jun Xian Yuen³, Cheryl Cheng Yee Tan², Daniel Rui Xiang Lim², Hao Ling Tang², Qi Gao³, Tun Linn THEIN⁴, Matthias Paul Han Sim Toh⁴, Sapna Pradip SADARANGAN⁴, ¹*Tan Tock Seng Hospital, Singapore,* ²*National Public Health Laboratory, Singapore,* ³*Singapore Communicable Diseases Agency and Planning Office, Singapore,* ⁴*Tan Tock Seng Hospital National Centre for Infectious Diseases, Singapore*

[P1.74]

Mpox vaccine intention undermined by conspiracy beliefs among Americans

Eric Walsh-Buhi^{1,2}, Margaret Walsh-Buhi³, ¹*Indiana University Bloomington School of Public Health, USA,* ²*Indiana University Melvin and Bren Simon Comprehensive Cancer Center, USA,* ³*Indiana University Bloomington, USA*

[P1.75]

Electroporation-mediated delivery improves the immunogenicity of avian influenza DNA vaccines

Wenyu Liu, Jiaxin Yang, Ruhong Chen, Junjie Li, Pucheng Chen, Jinxiang Liu, Xianying Zeng, Guohua Deng, Jianzhong Shi, Yanbing Li, Yongping Jiang*, Hualan Chen, *State Key Laboratory for Animal Disease Control and Prevention, Harbin Veterinary Research Institute, CAAS, China*

[P1.76]

Recurrent measles outbreaks among young children in hard -to-reach communities – a public health challenge

Chen Stein-Zamir*, *Hebrew University of Jerusalem Faculty of Medicine, Israel*

[P1.77]

Development of a nipah vaccine exploiting the tag/catcher nanoparticle vaccine platform

Mireia Rocavert Barranco¹, Cyrielle Fougereux², Louise Goksøyr², Sven Hendrik Hagen², Anna Kathrine Okholm¹, Thor Grundtvig Theander¹, Morten Agertoug Nielsen¹, Willem Adriaan de Jongh², Adam Frederik Sander Bertelsen¹, ¹*Centre for Translational Medicine and Parasitology, Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark,* ²*AdaptVac Aps, Ole Maaløes Vej 3, 2200 Copenhagen N, Denmark*

[P1.78]

Lived Experiences and Perceptions of the COVID-19 Vaccine in South Africa: Insights into Hesitancy, Trust, and Uptake

Thabisile Qwabi¹, Shabnam Shaik¹, Nomsa Ndaba¹, Anila Naz², Salima Siraj², Kimberley Gutu³, Clare Cutland⁴, Karina Top⁵, ¹University of the Witwatersrand Johannesburg Vaccines and Infectious Diseases Analytics Research Unit, South Africa, ²University of Alberta Faculty of Nursing, Canada, ³Wits-ALIVE University of the Witwatersrand, South Africa, ⁴Wits-ALIVE University of the Witwatersrand, South Africa, ⁵University of Alberta, Canada

[P1.79]

Psycho-social correlates of COVID-19 vaccine uptake, second dose, and booster in Hispanic/Latino sexual and gender minority populations in the U.S.

Casey Xavier Hall^{1,2}, Crim Sabuncu^{1,2}, Brittany Lane¹, Beth Okantey^{1,2}, Frankie Wong^{1,2}, Eugenia Millender^{1,2}, ¹Florida State University, College of Nursing, Center of Population Sciences for Health Empowerment, USA, ²Florida State University, College of Social Work, USA

[P1.80]

Assessment of Immunogenicity and Safety of the live attenuation Varicella Vaccine (Barycela) in Adolescents and Adults

Hyun Mi Kang¹, Yoon Kyung Cho¹, Ye Ji Kim¹, Bin Ahn², Gwanglok Kim³, Raeseok Lee⁴, ¹Department of Pediatrics, College of Medicine, The Catholic University of Korea, Republic of Korea, ²Department of Pediatrics, Seoul Metropolitan Government - Seoul National University Boramae Medical Center, Republic of Korea, ³Department of Corporate Development, GC Biopharma Corporation, Republic of Korea, ⁴Division of Infectious Diseases, Department of Internal Medicine, The Catholic Blood and Marrow Transplantation Center, The Catholic University of Korea College of Medicine, Republic of Korea

[P1.81]

Japanese encephalitis live attenuated chimeric vaccine administered intradermally provides short and long term seroprotection: A useful dose sparing strategy

Nicholas Wood^{1,2}, Emma Goeman², Narayan Gyawali³, Nirupama Nammunige⁴, Alison Nikitas⁵, Isobel Li⁶, Ian Marschner⁶, Keira Glasgow⁷, Jennifer Case⁷, Greg Devine⁴, Colleen Lau⁸, Luis Furuya Kanamori⁸, ¹The University of Sydney, Australia, ²National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, Australia, ³Queensland Health, Australia, ⁴QIMR Berghofer Medical Research Institute, Australia, ⁵Murrumbidgee Local Health District, Australia, ⁶NHMRC Clinical Trials Centre, Australia, ⁷New South Wales Ministry of Health, Australia, ⁸The University of Queensland, Australia

[P1.82]

Li-RA : a 3 in 1 vaccine to fortify the defences against melioidosis

Jeremy Aboagye¹, Nicole O'Sullivan¹, Julen Tomás-Cortazar², Siobhán McClean², Ed Lavelle¹, Gabriel Kristian Pedersen³, ¹Trinity College Dublin Biomedical Sciences Institute, Ireland, ²University College Dublin, Ireland, ³Statens Serum Institut, Denmark

[P1.83]

Oligopeptide binding protein A is a potential vaccine target to control Salmonella infection

Ken Yoshii¹, Koichiro Suzuki^{1,2,3}, Jun Adachi⁴, Eri Node¹, Zilai Liu^{1,5}, Takahiro Nagatake^{1,6}, Koji Hosomi^{1,7}, Jun Kunisawa^{1,5,8,9,10,11,12,13,14}, ¹Laboratory of Vaccine Materials and Laboratory of Gut Environmental System, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBN), Japan, ²The Research Foundation for Microbial Diseases of the University of Osaka, Japan, ³BIKEN-RIMD NGS Laboratory, Research Institute for Microbial Diseases, The University of Osaka, Japan, ⁴Laboratory of Proteomics for Drug Discovery, National Institutes of Biomedical Innovation, Health and Nutrition (NIBN), Japan, ⁵Graduate School of Pharmaceutical Sciences, The University of Osaka, Japan, ⁶Laboratory of Functional Anatomy, Department of Life Sciences, School of Agriculture, Meiji University, Japan, ⁷Graduate School of Veterinary Science, Osaka Metropolitan University, Japan, ⁸Graduate School of Medicine, The University of Osaka, Japan, ⁹Graduate School of Dentistry, The University of Osaka, Japan, ¹⁰Graduate School of Science, The University of Osaka, Japan, ¹¹International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Japan, ¹²Department of Microbiology and Immunology, Kobe University Graduate School of Medicine, Japan, ¹³Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan, ¹⁴Research Organization for Nano and Life Innovation, Waseda University, Japan

[P1.84]

The challenge of Pertussis (Whooping cough) burden in young infants under one year of age

Chen Stein-Zamir^{*}, Hebrew University of Jerusalem Faculty of Medicine, Israel

[P1.85]

Factors Influencing the Decision to Receive the HPV Vaccine in Kanagawa Prefecture, Japan

Tomohiro Katsuta¹, Hiroyuki Shimizu², Kenichi Nishimura³, Yukitsugu Nakamura¹, Hiroyuki Aiba¹, Tomoyuki Imagawa⁴, Toshihiro Tanaka⁵, Nao Suzuki⁶, Naoki Shimizu¹, Etsuko Miyagi⁷, Shuichi Ito³, ¹Department of Pediatrics, St. Marianna

University School of Medicine, Japan,²Department of Clinical Laboratory Medicine, Fujisawa City Hospital, Japan,³Department of Pediatrics, Graduate School of Medicine, Yokohama City University, Japan,⁴Department of Infectious Disease and Immunology, Kanagawa Children's Medical Center, Japan,⁵Department of Pediatrics, Shizuoka Kosei Hospital, Japan,⁶Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Japan,⁷Department of Obstetrics and Gynecology, Yokohama City University Graduate School of Medicine, Japan

[P1.86]

Study on the immunogenicity of a recombinant baculovirus-based human norovirus vaccine candidate

Doyoung Yoon*, Youngjik Lee, Young Bong Kim, Hee-Jung Lee, Konkuk University, Republic of Korea

[P1.87]

Low energy electron irradiation for the inactivation of pathogens in liquids for vaccine production

Jasmin Fertey¹, Gustavo Makert¹, Leila Issmail¹, Martin Thoma², Simone Schopf³, Thomas Grunwald¹, Sebastian Ulbert¹, ¹Fraunhofer Institute for Cell Therapy and Immunology IZI, Germany,²Fraunhofer Institute for Manufacturing Engineering and Automation IPA, Germany,³Fraunhofer Institute for Electron Beam and Plasma Technology FEP, Germany

[P1.88]

Systematic Review Protocol: Establishment and Analysis of Landscapes for Candidate Platforms and Vaccines Against Current and Emerging Viral Threats

Amit Bansal¹, Tung Thanh Le², Stig Tollefsen², Thorkild Tylleskär³, Kurt Hanevik¹, Bjørn Blomberg¹, Karl Albert Brokstad¹, Rebecca Jane Cox¹, Rishi Delan Pathirana¹, ¹Department of Clinical Science, University of Bergen, Bergen, Norway,²The Coalition for Epidemic Preparedness Innovations, Oslo, Norway,³Centre for International Health, University of Bergen, Bergen, Norway

[P1.89]

Estimating the rate of vaccination and identifying associated factors influencing childhood vaccination uptake

Lindi Mathebula¹, Moleen Dzikiiti², Charles Wiysonge¹, ¹Cochrane South Africa, South African Medical Research Council, South Africa,²Stellenbosch University, South Africa

[P1.90]

Immune boosting and the perils of interpreting pertussis seroprevalence studies

Matthieu Domenech de Cellès¹, Anabelle Wong^{*1,2}, Tine Dalby³, Pejman Rohani^{4,5,6}, ¹Max-Planck-Institute for Infection Biology, Germany,²Institute of Public Health, Charité – Universitätsmedizin Berlin, Germany,³Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Denmark,⁴University of Georgia Odum School of Ecology, USA,⁵Center of Ecology of Infectious Diseases, USA,⁶Department of Infectious Diseases, College for Veterinary Medicine, University of Georgia, USA

[P1.91]

Sublingual Vaccine Formulation with SARS-CoV-2 RBD or Influenza HA Antigen and Poly(I:C) Adjuvant and Mechanism Underlying Immune Responses Elicited by Sublingual Vaccine

Tetsuro Yamamoto^{1,2}, Fusako Mitsunaga^{3,4}, Atsushi Kotani^{1,2}, Kazuki Tajima^{1,2}, Shin Nakamura^{*3,4}, ¹Innovation Research Center, EPS Holdings, Inc, Japan,²Research Center, EPS Innovative Medicine Co., Ltd, Japan,³Intelligence & Technology Lab, Inc, Japan,⁴Biomedical Institute, NPO Primate Agora, Japan

[P1.92]

Genular: an integrated platform for defining cellular identity and function through single-cell gene expression and multi-domain biological data

Ivan Tomic*, Boston University, USA

[P1.93]

Paediatric varicella epidemiology in urban Beijing, China, 2014–2023

Dan Yu¹, Wei Su², Miao Fan¹, Lu Lu¹, Xinyu Wang¹, Sheng Zhang³, Qingjing Du³, Lin Ma¹, Ying Liu¹, Kaihu Yao¹, ¹Beijing Children's Hospital Capital Medical University, China,²Children's Hospital Affiliated to Capital Institute of Pediatrics, China,³Children's Hospital Affiliated to Capital Institute of Pediatrics, China

[P1.94]

Effect of Vaccination for Porcine Respiratory Disease Complex on Porcine Gut Microbiome

Yeonsu Oh¹, Zoya Afzal¹, Md Jamilur Rahman¹, Young-Seung Ko², Sung-Hyun Moon², Seung-Hun Lee³, Ho-Seong Cho², ¹College of Veterinary Medicine and Institute of Veterinary Science, Kangwon National University, Chuncheon 24341,

[P1.95]

Integrated Process Development for Template DNA and mRNA Drug Substance in Vaccine Production

Kumi Fukushima*, Hideto Chono, Takara Bio Inc, Japan

[P1.96]

Optimization of RNA Manufacturing Process

Kensuke Abe*, Yuzuru Sugio, Masaaki Ouchi, Yoshinori Katayama, Takara Bio Inc., Japan

[P1.97]

Establishment of an advanced preclinical model for Rift Valley fever (RVF) virus for the assessment of vaccine efficacy.

Emma Kennedy*, Kimi Ebisine, Darcy Quist, Stephen Findlay-Wilson, Stuart Dowall, UK Health Security Agency Porton, UK

[P1.98]

Development and Evaluation of Novel Multi-Epitope DNA Vaccine Candidates for African Swine Fever: Integrating B-Cell and T-Cell Immunity

Namphueng Butkhot*, Kanokporn Polyiam, Yaowaluck Maprang Roshorm, King Mongkut's University of Technology Thonburi, Thailand

[P1.99]

Humoral and cellular immune responses against SARS-CoV-2 following COVID-19 vaccination in older adults. A systematic review

Nelson Luis Cahuapaza-Gutierrez*, Cielo Cinthya Calderon-Hernandez, Ruth Angélica Rojas-De la cruz, Janeth M. Flores-Córdova, Fernando M. Runzer-Colmenares, Universidad Científica del Sur, Peru

[P1.100]

Endocrine disorders following SARS-CoV-2 vaccination. A comprehensive systematic review.

Cielo Cinthya Calderon-Hernandez¹, Romina Maria Barrera-Quispe^{*1}, Nelson Luis Cahuapaza-Gutierrez¹, Tatiana Vanessa Villavicencio-Escudero¹, Claudia Vanessa Ibárcena-Llerena², Cristina Quiroz-Narvaez¹, Helya Yusara Coronado-Quispe¹, ¹Universidad Científica del Sur, Peru, ²Department of Endocrinology, Clínica Internacional Sede San Borja, Peru

[P1.101]

Factors associated with HPV vaccine acceptance and hesitancy in Low and Middle-Income Countries: a prevalence systematic review.

Anelisa Jaca^{*1}, Edison Mavundza², Duduzile Ndwandwe², ¹Cochrane South Africa, South African Medical Research Council, Cape Town, South Africa, ²South African Medical Research Council, South Africa

[P1.102]

A novel approach to immune compromised Hepatitis B non-responders

Kaz Bellamy, Cathy Boundy, Guillian Hunter*, Monash Health, Australia

[P1.103]

Barriers to vaccination uptake for key vaccine preventable diseases among Lesbian, gay, bisexual, transgender, and queer individuals in living in two US States

Kristen D. Krause^{*1,2}, Paul A. D'Avanzo², Kendra I. Lewis^{1,2}, Perry N. Halkitis^{1,2}, ¹Rutgers School of Public Health, USA, ²Center for Health Identity Behavior and Prevention Studies, USA

[P1.105]

Employer Health Insurance as a Policy Pathway to Improving Adult Vaccination in India

Arindam Ray^{*1}, Kavita Chauhan², Ajay Vamadevan³, Praveen Pradeep³, ¹Gates Foundation, India, ²Oxford Policy Management, UK, ³Goa Institute of Management, India

[P2.01]

Post Rota vaccination scenario of Rota viral diarrhoea among children aged six months to three years in Odisha, India – A community based study

Ashoka Mahapatra^{*1}, Kavita Gupta², Arvind Kumar Singh¹, Bhagirathi Dwivedi¹, Jitendriya Amrit Pritam¹, ¹All India Institute of Medical Sciences Bhubaneswar, India, ²AIIMS Bhubaneswar, India

[P2.02]

Subacute Sclerosing Panencephalitis Incidence Following Measles Outbreak in the Republic of Korea

Young June Choe^{*}, Korea University, Republic of Korea

[P2.03]

Navigating social and political lessons of vaccination policies from the COVID-19 pandemic

Trenton White^{1,2}, Jeffrey V. Lazarus^{2,1}, Ayman El-Mohandes², ¹Barcelona Institute for Global Health, Spain, ²CUNY Graduate School of Public Health & Health Policy, USA

[P2.04]

Analysis on epidemiological characteristics of major respiratory infectious diseases in Baiying from 2014 to 2023

Zongying Zhan¹, Tiancheng Xie^{*2}, Tianshuo Zhao³, Xiyu Zhang³, Sihui Zhang³, Mingting Wang³, Qingsong Xu³, Yujie Cheng³, Shubo Yang⁴, Fuqiang Cui³, ¹Department of Public Health, Jingyuan County People's Hospital, Baiyin City, Gansu Province, China, ²Peking University, China, ³Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China, ⁴Baiyin City Center for Disease Control and Prevention, Gansu Province, China

[P2.05]

Clinical outcomes of influenza infection in hospitalized children between 2018 and 2023

Bera Enes Seyrek^{*1}, Oğuz Osman Demir², Kubra Aykac², Ali Bulent Cengiz², Yasemin Ozsurekci², ¹Hacettepe University Faculty of Medicine, Turkey, ²Hacettepe University Hospitals, Turkey

[P2.06]

Impact of the Pandemic Measures on Respiratory Syncytial Virus Associated Diseases in Children and Latest Updates in the Post-Pandemic Period: The Situation in Türkiye in Pre-vaccine Era

Irem Kalkan^{*}, Kubra Aykac, Hande Kahya, Sema Aydın, Osman Oguz Demir, Ali Bulent Cengiz, Yasemin Ozsurekci, Hacettepe University Institute of Child Health, Turkey

[P2.07]

Extrapulmonary manifestation of Respiratory Syncytial Virus

EDA gökçay^{*}, Yasemin Ozsurekci, Kubra Aykac, Ali Bülent Cengiz, Zehra Yapicioglu Keskin, Busra UNAL, osman oğuz Demir, Hacettepe University Faculty of Medicine, Turkey

[P2.08]

The stability and immunogenicity of formalin-inactivated Enterovirus A71 whole virion vaccine after ten years of low temperature storage

Yu-Sheng Shen¹, Yen-Hung Chow¹, Chih-Yeu Fang¹, Shang-Rung Wu², Chi-Hsun Chen³, Ming-Hsi Huang¹, Ching-Len Liao¹, Jen-Ron Chiang¹, Chia-Chyi Liu^{*1}, ¹National Health Research Institutes, Taiwan, ²National Cheng Kung University Institute of Oral Medicine, Taiwan, ³National Tsing Hua University Institute of Biotechnology, Taiwan

[P2.09]

Assessing the Impact of the Healthy Vaccinee Effect on COVID-19 Vaccine Effectiveness Estimates

Hiam Chemaitelly^{1,2}, Houssein H Ayoub³, Laith J Abu-Raddad^{*1,2}, ¹Weill Cornell Medicine - Qatar, Qatar, ²Weill Cornell Medicine, USA, ³Qatar University, Qatar

[P2.10]

Knowledge level regarding respiratory syncytial virus and the vaccine and its association with the vaccine acceptance among pregnant women in Japan

Masaki Machida^{*1,2}, Shigeru Inoue¹, Yuki Furuse³, Emiko Oka⁴, Yutaka Ueda⁴, Shinji Fukushima², Takahiro Tabuchi⁵, ¹Tokyo Medical University, Japan, ²Tokyo Medical University Hospital, Japan, ³The University of Tokyo, Japan, ⁴Osaka University Graduate School of Medicine Department of Obstetrics and Gynaecology, Japan, ⁵Tohoku University, Japan

[P2.11]

Development of a non-invasion Intranasal vaccine for *Klebsiella pneumoniae* urinary tract infection

L. Kristopher SIU^{*1}, Esther Yip-Mei Liu², Jung-Chung Lin², Ming-Hsi Huang¹, ¹National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Taiwan, ²Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taiwan

[P2.12]

Ovine respiratory syncytial virus: an overlooked contributor to pneumonia in sheep

Joan Lloyd^{*1,2}, Tom Clune², Caroline Jacobson², Johann Schroder³, ¹Joan Lloyd Consulting Pty Ltd, Australia, ²Murdoch University, Australia, ³Gemini R&D Services, Australia

[P2.13]

Advancing mRNA vaccine research and development in Malaysia: A journey of international collaboration

Hai Yen Lee^{*}, Siau Xuan Chong, Phui Chyng Yap, Wei Teck Ong, Siti Nur Zakiah Salimon, Jonald Rui Teng Low, Min Sin Toh, University of Malaya Tropical Infectious Diseases Research and Education Centre, Malaysia

[P2.14]

Advancing Synthetic Nucleotides for Next-Generation Human and Veterinary Flaviviral Vaccines

Gerry Amor Camer^{*1,2}, Taichi Endoh², Hiroki Teraoka², Kotetsu Kayama³, Daiji Endoh⁴, ¹University of Eastern Philippines - College of Veterinary Medicine, The Philippines, ²Rakuno Gakuen University, Japan, ³Medical Corporation Tetsuryukai, Kasai Home Care Clinic, 101, 18-12 Nakakasai 8-chome, Edogawa-ku, Tokyo 134-0083, Japan, ⁴Knowledge Connect, and Research Institute for Advanced Nursing and Technology, Japan

[P2.15]

Cost-effective and small foot-print upstream process development and scale-up for vaccines, using fixed-bed bioreactor technology, Sabin inactivated polio vaccine as a case study

Ahd Hamidi^{*}, Wilfried Bakker, Batavia Biosciences BV, The Netherlands

[P2.16]

Determining Factors for Incompletion of Child's Routine Immunization at Conflict-Affected Zones 2023-2024

Amna Khairy^{*1}, Almoghira Abdellah², ¹Eastern Mediterranean Public Health Network, Jordan, ²Republic of Sudan Federal Ministry of Health, Sudan

[P2.17]

Virtual prenatal care and provider recommendations for influenza vaccination during pregnancy

Don Willis^{*1,2}, Cari Bogulski¹, Mahip Acharya³, Ji Li^{1,2}, James Selig^{3,1,2}, Jennifer Andersen^{1,2}, Nirvana Manning³, Pearl McElfish^{1,2}, ¹University of Arkansas for Medical Sciences - Northwest Regional Campus, USA, ²Institute for Community Health Innovation, USA, ³University of Arkansas for Medical Sciences, USA

[P2.18]

Age and sex modulate immunity induced by a SARS-CoV-2 virus-like particle vaccine in mice

Irem Evciil^{*}, Asena Sanli, Ismail Cem Yilmaz, Muzaffer Yildirim, Tugce Yildirim, Ihsan Gursel, Mayda Gursel, İzmir Biomedicine and Genome Center, Turkey

[P2.19]

Promotion of shared-decision making competencies among health care workers to increase vaccination rates against seasonal influenza in primary health care – a collaboration between the Zhejiang University (China) and LMU Munich (Germany)

Linda Sanftenberg^{*1}, Hongmei Wang², Yiqing Weng², Jochen Gensichen¹, ¹Institute of General Practice and Family Medicine, LMU University Hospital, LMU Munich, Germany, ²Department of Social Medicine, School of Public Health, Zhejiang University, China

[P2.20]

Outer membrane vesicles-based vaccine against chlamydia

Tamara Weinmayer^{*1}, Anna Pfundner¹, Nora Geißler¹, Viktor Cerny¹, Michael Thaler¹, Stefan Hein², Ursula Wiedermann¹, Irma Schabussova¹, Aleksandra Inic-Kanada¹, ¹Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Austria, ²Institute for Molecular Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria

[P2.21]

Targeting the Unreached: Strengthening Primary Health Care to Improve Immunization Coverage Among Zero-Dose and Under-Immunized Children in West Nile, Uganda

DANIEL Kiiza^{*1}, Boneventure Kawere¹, Judith Nanyondo¹, Duncan Kabiito¹, Andrew Kwiringira¹, Gerald Aluma¹, Bruno Ocen¹, Rita Atugonza², Michael Baganizi², Shibani Kulkani³, Maureen Kesande¹, Dathan Byonanebye¹, Francis Kakooza¹, Ledor Igboh³, Yvette Wibabara⁴, Ciara Sugerman³, ¹*Makerere University Infectious Diseases Institute, Uganda*, ²*Republic of Uganda Ministry of Health, Uganda*, ³*Centers for Disease Control and Prevention, USA*, ⁴*Centers for Disease Control and Prevention Global Health Uganda, Uganda*

[P2.22]

Physiologically Relevant Epitope Discovery Platform: DF-1-Based MHC-I Peptidomics for T Cell Vaccine Development

Sunmin Ahn^{*1}, Hyuk-Joon Kwon¹, Kang-Seuk Choi², Howon Kim², Seung-Ji Kim², ¹*Laboratory of Poultry Medicine, Department of Farm Animal Medicine, College of Veterinary Medicine and BK21 PLUS for Veterinary Science, Seoul National University, Republic of Korea*, ²*Laboratory of Avian Diseases, College of Veterinary Medicine, Seoul National University, Republic of Korea*

[P2.23]

Mechanisms of Squalene-Based Adjuvant A-910823: Modulating Vaccine Efficacy and Reactogenicity

Yuya Yoshioka^{*1}, Anri Yoshioka-Nishinaka¹, Kouji Kobiyama², Tomoya Hayashi², Yujiro Kidani¹, Yosuke Yanagida¹, Junpei Kasahara¹, Yoshiji Asaoka¹, Akimasa Yoshimura¹, Satoru Ishida¹, Shinya Omoto¹, Morio Nagira¹, Cevayir Coban³, Ken J. Ishii², ¹*Shionogi and Co Ltd, Japan*, ²*The University of Tokyo Institute of Medical Science Division of Vaccine Science, Japan*, ³*The University of Tokyo Institute of Medical Science Division of Malaria Immunology, Japan*

[P2.24]

Humoral immunity is insufficient to prevent reinfection with Omicron subvariants in the upper airway

Nozomi Shiwa-Sudo^{*}, Yusuke Sakai, Naoko Iwata-Yoshikawa, Shinji Watanabe, Souichi Yamada, Yudai Kuroda, Tsukasa Yamamoto, Masayuki Shirakura, Seiichiro Fujisaki, Kaya Miyazaki, Hideka Miura, Shiho Nagata, Shuetsu Fukushi, Ken Maeda, Hideki Hasegawa, Tadaki Suzuki, Noriyo Nagata, *National Institute of Infectious Diseases, Japan Institute for Health Security, Japan*

[P2.25]

Physicochemical protein engineering of VHH antibodies against infection-related antigens

Satoru Nagatoishi^{*}, Kouhei Tsumoto, *The University of Tokyo, Japan*

[P2.26]

Enhancing Immune Protection in Cattle: The Role of *Escherichia coli* Nissle 1917 in Boosting the Efficacy of a *M. bovis*-BoHV-1 Combined Vaccine

Sen Zhang^{*}, Aizhen Guo, Yingyu Chen, *Huazhong Agricultural University, China*

[P2.27]

Glycan masking of epitopes in NTD and RBD as a vaccine design strategy against SARS-CoV-2 variants

Hao-Chan Hung¹, Boon-Fatt Tan², Wei-Shuo Lin¹, Suh-Chin Wu^{*1}, ¹*National Tsing Hua University College of Life Sciences and Medicine, Taiwan*, ²*National Taiwan University Hospital Hsinchu Branch, Taiwan*

[P2.28]

Development of an mRNA vaccine expressing virus-like particles (VLPs) of Enterovirus D68 (EV-D68)

Yuta Kunishima^{*1,2}, Kota Senpuku^{1,3}, Kotaro Taniguchi^{1,3}, Tatsuya Karaki^{1,2}, Chikako Nakamura-Kataoka², Toshiro Hirai^{1,3,4,5}, Yasuo Yoshioka^{1,2,3,4,5}, ¹*Vaccine Creation Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Research Institute for Microbial Diseases, The University of Osaka, Japan*, ²*The Research Foundation for Microbial Diseases of Osaka University, Japan*, ³*Laboratory of Nano-design for Innovative Drug Development, Graduate School of Pharmaceutical Sciences, The University of Osaka, Japan*, ⁴*Vaccine Creation Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Institute for Open and Transdisciplinary Research Initiatives, The University of Osaka, Japan*, ⁵*Center for Advanced Modalities and DDS, The University of Osaka, Japan*

[P2.29]

Immune Response, Safety, and Psychological Aspects of COVID-19 Vaccination: Insights from Kidney Transplant Patients and Healthcare Workers

Jolanta Sauserienė^{*}, Rūta Vaičiūnienė, Brigita Gradauskienė, Leonas Valius, Ida Liseckienė, Danielius Serapinas, *Lithuanian University of Health Sciences, Lithuania*

[P2.30]

Vaccine impact of hypothetical Nipah virus vaccine in Bangladesh and India [Work in progress]

Sol Kim*, Nagasaki University, Japan, London School of Hygiene & Tropical Medicine, UK

[P2.31]

Evaluation of different live Infectious Bovine Rhinotracheitis (IBR) marker vaccines to protect the calves from wild-type Bovine alphaherpesvirus 1 (BoAHV-1) induced viral latency^o

Cecilia Righi¹, Alessandra Martucciello², Giovanna Cappelli², Claudia Torresi¹, Eleonora Scoccia¹, Carlo Grassi², Monica Giammarioli¹, Giulia Costantino¹, Esterina De Carlo², Cristina Casciari¹, Roberto Sabato¹, Francesco Feliziani¹, Stefano Petrini¹, ¹National Reference Centre for Infectious Bovine Rhinotracheitis (IBR), Istituto Zooprofilattico Sperimentale Umbria-Marche, "Togo Rosati," Perugia, Italy, Italy, ²National Reference Centre for Hygiene and Technology of Breeding and Buffalo Production, Istituto Zooprofilattico Sperimentale del Mezzogiorno, Salerno, Italy, Italy

[P2.32]

Evaluation of the Immunomodulatory Effects of Androia Camphorata Extract on Dairy Cows

Yu-I Pan^{*1,2,3}, Geng-Ming Jhang⁴, Chun-Yen Chu⁴, Jai-wei Lee⁵, ¹Department of Veterinary Medicine, College of Veterinary Medicine, National Pingtung University of Science and Technology, Taiwan, ²Veterinary Medical Teaching Hospital, Department of Veterinary Medicine, College of Veterinary Medicine, National Pingtung University of Science and Technology, Taiwan, ³Research Center of Animal Biologics, National Pingtung University of Science and Technology, Taiwan, ⁴Graduate Institute of Animal Vaccine Technology, National Pingtung University of Science and Technology, Taiwan, ⁵Department of Tropical Agriculture and International Cooperation, National Pingtung University of Science and Technology, Taiwan

[P2.33]

One vector, three threats: A trivalent vaccine against Malaria, SARS-CoV-2, and Mpox

Yuna Sato^{*1}, Yutaro Yamamoto¹, Ammar Abdurrahman Hasyim¹, Akihiko Sakamoto¹, Kartika Hardianti Zainal¹, Takeshi Morita², Koichi Watashi², Mitsuhiro Iyori³, Hiroaki Mizukami⁴, Hisatoshi Shida⁵, Shigeto Yoshida¹, ¹Laboratory of vaccinology and Applied Immunology, Kanazawa University School of Pharmacy, Japan, ²Department of Drug Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Japan, ³Research Institute of Pharmaceutical Sciences, Musashino University, Japan, ⁴Division of Genetic Therapeutics, Jichi Medical University, Japan, ⁵Laboratory of Primate Model, Research Center for Infectious Diseases, Institute for Frontier Life and Medical Science, Japan

[P2.34]

Genomic and structural determinants of infectious bronchitis virus adaptation in chicken embryo kidney cells: Implications for viral tropism and vaccine safety

Seungmin Hong^{*1}, Se-Hee An², Kang-Seuk Choi¹, Hyuk-Joon Kwon^{1,3}, ¹Laboratory of Avian Diseases, College of Veterinary Medicine, BK21 plus Program for Veterinary Science and Research Institute for Veterinary Science, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 151-742, Republic of Korea, ²Avian Disease Division, animal and Plant Quarantine Agency, Gimcheon, Gyeongsangbuk-Do, 39660, Republic of Korea, ³Laboratory of Poultry Production Medicine, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 151-742, Republic of Korea

[P2.35]

Assessment of animal models for severe Mpox: A comparative study of macaques and marmosets

Noriyo Nagata*, Masayuki Shimojima, Kenzo Yonemitsu, Yusuke Sakai, Naoko Iwata-Yoshikawa, Tomoki Yoshikawa, Takeshi Kurosu, Shuetsu Fukushi, Shuji Ando, Mutsuyo Takayama-Ito, Chang-Kweng Lim, Madoka Kawahara, Kohei Oishi, Yasushi Ami, Hideki Hasegawa, Shigeru Morikawa, Masayuki Saijo, Hideki Ebihara, Tadaki Suzuki, National Institute of Infectious Diseases, Japan Institute for Health Security, Japan

[P2.36]

Safety profile and medium- to long-term protection of the Recombinant Zoster Vaccine (RZV) in a cohort of high-risk patients: real-world data from a General Hospital in Southern Italy

Pasquale Stefanizzi, Lorenza Moscara, Claudia Palmieri*, Andrea Martinelli, Antonio Di Lorenzo, Chiara Scaltrito, Petra Buonvino, Silvio Tafuri, University of Bari Interdisciplinary Department of Medicine, Italy

[P2.37]

Immunogenicity of an intranasal dual (surface and core)-antigen vaccine against hepatitis B virus enhanced by carboxyl-vinyl polymer excipients

Md Haroon Or Rashid^{*1}, Fumihiko Yasui², Takahiro Sanada², Risa Kono², Bouchra Kitab¹, Yasumasa Goh³, Takashi Miyazaki⁴, Michinori Kohara², Kyoko Tsukiyama-Kohara¹, ¹Kagoshima University, Japan, ²Tokyo Metropolitan Institute of Medical Science, Japan, ³Beacle Co., Japan, ⁴Toko Yakuhin Co., Japan

[P2.38]

Tensions between regional and global interests in enabling robust vaccine procurement policies

David Robins*, Farshid Babaei, Solomon Brown, *The University of Sheffield, UK*

[P2.39]

A trivalent intranasal SARS-CoV-2 vaccine broadly neutralizes divergent variants, and intranasal boosting enhances hybrid immunity in mice

Stefan Slamanig*^{1,2}, Marta Boza¹, Jordan Clark¹, Michael Scherm¹, Tsoi Ying Lai¹, Adam Abdeljawad¹, Dilhan Perera¹, Kevin Ding¹, William Shea¹, Benhur Lee¹, Irene González-Domínguez¹, Florian Krammer^{1,3,4,5}, Peter Palese^{1,6}, Weina Sun¹, ¹*Icahn School of Medicine at Mount Sinai Department of Microbiology, USA*, ²*University of Amsterdam Swammerdam Institute for Life Sciences, The Netherlands*, ³*Icahn School of Medicine at Mount Sinai, Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), USA*, ⁴*Icahn School of Medicine at Mount Sinai, Department of Pathology, Molecular and Cell-Based Medicine, USA*, ⁵*Medical University of Vienna, Ignaz Semmelweis Institute, Interuniversity Institute for Infection Research, USA*, ⁶*Icahn School of Medicine at Mount Sinai, Department of Medicine, Division of Infectious Diseases, USA*

[P2.40]

Development and Immunogenicity Evaluation of a Bivalent Subunit Vaccine Against Porcine Circovirus Type 2 and Classical Swine Fever Virus

Chi-Chih Chen*, Yu-Chieh Chen, Ya-Mei Chen, *Reserch Center for Animal Biologics, College of Veterinary Medicine, National Pingtung University of Science and Technology, Taiwan*

[P2.41]

Serotype distribution of Group B Streptococcus in maternal colonization and infant invasive disease: systematic review and meta-analysis

Prabha Andraweera*^{1,2}, Kaitlyn Millar¹, Nicholas Jewell¹, Sarah Aylward¹, Bing Wang^{1,2}, Hassen Mohammed^{1,2}, Mark McMillan^{1,2}, Helen Marshall^{1,2}, ¹*The University of Adelaide Adelaide Medical School, Australia*, ²*Women's and Children's Hospital Adelaide, Australia*

[P2.42]

Under what circumstances are pandemic vaccine mandates ethically justifiable?

Jane Williams*¹, Julie Leask¹, Shevaun Drislane², Jess Kaufman³, Marco Rizzi², Katie Attwell², ¹*The University of Sydney, Australia*, ²*The University of Western Australia, Australia*, ³*Murdoch Children's Research Institute, Australia*

[P2.43]

Activation of the cGAS-IFN-I axis by nucleocytoysis

Hideo Negishi*^{1,2,3,4}, Yusuke Wada¹, Yoshitaka Shirasaki⁵, Tomoya Hayashi^{1,2,4}, Yuji Kubota⁶, Mina Kurosawa¹, Toru Suzuki⁷, Mai Yamagishi⁸, Burcu Temizoz^{1,2,9}, Atsushi Iwama^{4,10,11}, Toshifumi Inada^{4,7}, Etsushi Kuroda¹², Kouji Kobiyama^{1,2,4}, Noriko Toyama-Sorimachi², Mutsuhiro Takekawa^{4,6,13}, Cevayir Coban^{2,4,14}, Ken Ishii^{1,2,4}, ¹*Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Japan*, ²*International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, Japan*, ³*Laboratory of Immunology and Infection Control, Institute for Quantitative Biosciences, The University of Tokyo, Japan*, ⁴*The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), The University of Tokyo, Japan*, ⁵*Division of Photonic Imaging, Research Center for Advanced Science and Technology, The University of Tokyo, Japan*, ⁶*Division of Cell Signaling and Molecular Medicine, The Institute of Medical Science, The University of Tokyo, Japan*, ⁷*Division of RNA and gene regulation, The Institute of Medical Science, The University of Tokyo, Japan*, ⁸*Live Cell Diagnosis, Ltd., Japan*, ⁹*The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), Japan*, ¹⁰*Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Japan*, ¹¹*Laboratory of Cellular and Molecular Chemistry, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Japan*, ¹²*Department of Immunology, Hyogo College of Medicine, Japan*, ¹³*Medical Proteomics Laboratory, The Institute of Medical Science, The University of Tokyo, Japan*, ¹⁴*Division of Malaria Immunology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Japan*

[P2.44]

The effectiveness of JN.1 COVID-19 vaccine in South Korea: interim analysis

Hakjun Hyun¹, Jang Wook Sohn², Won Seok Choi³, Seong-Heon Wie⁴, Jacob Lee⁵, Jin-Soo Lee⁶, Hye Won Jeong⁷, Joong Sik Eom⁸, Ju Jung Choi⁵, Jin Gu Yoon⁵, Eliel Nham⁵, Ji Yun Noh⁵, Joon Young Song⁵, Woo Joo Kim⁵, Hee Jin Cheong⁵, ¹*Ajou University School of Medicine, Republic of Korea*, ²*Korea University Anam Hospital, Republic of Korea*, ³*Korea University Ansan Hospital, Republic of Korea*, ⁴*The Catholic University of Korea St Vincent's Hospital, Republic of Korea*, ⁵*Korea University Guro Hospital, Republic of Korea*, ⁶*Inha University School of Medicine, Republic of Korea*, ⁷*Chungbuk National University College of Medicine, Republic of Korea*, ⁸*Gachon University Gil Medical Center, Republic of Korea*

[P2.45]

Circadian rhythm influences flu vaccine-specific respiratory responses

Divya Sinha¹, Xinchun Yuan¹, Salma Bessalah¹, Iuliia Konstantinova¹, Blandine Noailly¹, Fabienne Jospin¹, Stephane Paul^{1,2}, Stephanie Longet^{*1}, ¹Jean Monnet University, France,²University Hospital Centre Saint-Étienne, France

[P2.46]

Cross-protective efficacy of HA-mRNA vaccine against antigenically drifted avian influenza virus

Tsai-Teng Tzeng^{*1}, Sing-Ru Lai¹, Kit Man Chai¹, Fang-Feng Chiu¹, Shih-Jen Liu^{1,2,3}, ¹National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Taiwan,²Graduate Institute of Biomedical Sciences, China Medical University, Taiwan,³Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Taiwan

[P2.47]

Parents hesitate to vaccinate themselves and their children against COVID-19 in Taiwan

Yung-Hsien Tung¹, Tao-Hsin Tung^{*2}, ¹Department of Sport Medicine, Kaohsiung Medical University, Taiwan,²Evidence-based Medicine Center, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, China

[P2.48]

Dengue in travellers returning to England: first analysis of dengue preventative behaviours among dengue cases, using a new enhanced national surveillance system

Jin-Min Yuan^{*1}, Iman Mohamed², Daniel Stewart³, Jane Osborne⁴, Philip Veal², Hilary Kirkbride², ¹Field Epidemiology Training Programme, UKHSA, UK,²Travel Health and International Health Regulations team, UKHSA, UK,³Field Services, UKHSA, UK,⁴Rare and Imported Pathogens Laboratory, UKHSA, UK

[P2.49]

Do Vaccine Mandates Impair the Voluntariness of Informed Consent?

Maxwell Smith^{*1}, Evan Mackie², ¹Western University, Canada,²Carleton University, Canada

[P2.50]

The Contribution of Ethical Concerns to Vaccine Hesitancy: A Scoping Review

Maxwell Smith^{*}, Sarah Ashfield, Western University, Canada

[P2.51]

Streamlined plasmid DNA manufacturing: enabling innovation in vaccines and therapies today

Salomé de Sá Magalhães^{*}, Eli Keshavarz-Moore, University College London, UK

[P2.52]

A single immunization with intranasal Newcastle disease virus (NDV)-based XBB. 1.5 variant vaccine reduces disease and transmission in animals against matched-variant challenge

Stefan Slamanig^{1,2}, Nicholas Lemus¹, Tsoi Ying Lai¹, Gagandeep Singh^{1,3}, Adam Abdeljawad¹, Marta Boza¹, Mitali Mishra¹, Victoria Dolange¹, Gagandeep Singh^{1,4}, Benhur Lee¹, Irene González-Domínguez¹, Michael Schotsaert^{1,3,5,6}, Florian Krammer^{1,7,8,9}, Peter Palese^{1,10}, Weina Sun^{*1}, ¹Icahn School of Medicine at Mount Sinai Department of Microbiology, USA,²University of Amsterdam, The Netherlands,³Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, USA,⁴Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, USA,⁵Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, USA,⁶Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, USA,⁷Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, USA,⁸Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, USA,⁹Ignaz Semmelweis Institute, Interuniversity Institute for Infection Research, Medical University of Vienna, Austria,¹⁰Icahn School of Medicine at Mount Sinai Department of Medicine, USA

[P2.53]

The protective limits of social capital: How information inconsistent with current scientific evidence influence COVID-19 vaccination intentions

Yutaro Furukawa^{*1}, Mikiko Tokiya², Yuichiro Nishida¹, Takuma Furukawa¹, Takaomi Kobayashi¹, Wakaba Fukushima³, Megumi Hara¹, ¹Department of Preventive Medicine, Saga University, Japan,²Department of Social and Environmental Medicine, Saga University, Japan,³Department of Public Health, Osaka Metropolitan University Graduate School of Medicine, Japan

[P2.54]

Pregnant women's choices for preventing respiratory syncytial virus (RSV)

Bing Wang^{1,2}, Prabha Andraweera^{1,2}, Gang Chen³, Jason Ong^{4,5}, Zohra Lassi¹, Helen Marshall^{6,2}, ¹The University of Adelaide, Australia, ²Women's and Children's Health Network, Australia, ³The University of Melbourne, Australia, ⁴Monash University, Australia, ⁵London School of Hygiene & Tropical Medicine, UK, ⁶The University of Adelaide School of Biological Sciences, Australia

[P2.55]

Early Tfh differentiation conversion thresholds govern influenza stem immunogenicity

Ming Z. M. Zheng*, Hyon-Xhi Tan, Lydia Murdiyarsa, Kathleen M. Wragg, Andrew Kelly, Robyn Esterbauer, Stephen J. Kent, Adam K. Wheatley, Jennifer A. Juno, *The Peter Doherty Institute for Infection and Immunity, Australia*

[P2.56]

Effectiveness of JN.1 COVID-19 Vaccine and Seasonal Influenza Vaccine During the 2024–2025 Season Among Adults Aged ≥18 Years in Japan: VERSUS Study, October 2024–March 2025

Haruka Maeda*, *VERSUS Group, Institute of Tropical Medicine, Nagasaki University, Japan*

[P2.57]

Attenuated Zika virus replicon-based self-amplifying RNA vaccine targeting SARS-CoV-2 KP.3 variant

Hye-Ri Oh*, Ji-Eun Kim¹, Seo-Yeon Hwang¹, Haewon Jung¹, Han Young Seo¹, Jong-Won Oh^{1,2}, ¹Department of Biotechnology, Yonsei University, Seoul 03722, Republic of Korea, ²RpexBio Inc., Yonsei University Engineering Park B140, Seoul 03722, Republic of Korea

[P2.58]

Development of heterologous PD-1 based DNA vaccines eliciting robust tissue-resident CD8+ T cell immunity against HIV-1 gastrointestinal reservoirs

Pengfei Zhang*, *The University of Hong Kong, Hong Kong*

[P2.59]

Anti-idiotypic antibody development for inducing broadly neutralizing antibody against SARS-CoV-2 variants

Yimei Wang*, Saya Moriyama¹, Yu Adachi¹, Akira Aina², Kenta Nakano³, Tadashi Okamura³, Tadaki Suzuki², Hiroshi Itou⁴, Yoshimasa Takahashi¹, ¹Research Center for Vaccine Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Japan, ²Department of Infectious Disease Pathology, National Institute of Infectious Diseases, Japan Institute for Health Security, Japan, ³Department of Laboratory Animal Medicine, National Institute of Global Health and Medicine, Japan Institute for Health Security, Japan, ⁴Drug Discovery Research, Chiome Bioscience Inc., Japan

[P2.60]

Evaluation of Highly-Efficient Cell-Adapted Live Attenuated Vaccine Candidate Against African Swine Fever Virus

Jong-Soo Lee¹, Sung-Sik Yoo², Weonhwa Jheong³, ¹College of Veterinary Medicine, Chungnam National University, Republic of Korea, ²Choong Ang Vaccine Laboratories, Republic of Korea, ³Wildlife Disease Response Team, National Institute of Wildlife Disease Control and Prevention, Republic of Korea

[P2.61]

Genomic and pathogenic characterization of a novel recombinant infectious bronchitis coronavirus isolated in Korea

Seung-Ji Kim*, Ho-Won Kim, Sun-Min Ahn, Jin-Ha Song, Seung-Eun Son, Ha-Na Park, So-Jeong Lim, Hyeon-Jin Sa, Kang-Seuk Choi, *Laboratory of Avian Diseases, College of Veterinary Medicine, Seoul National University, Republic of Korea*

[P2.62]

Characterization of an attenuated foot-and-mouth disease virus with critical mutations in VP1 and 3C

Jong-Soo Lee*, *College of Veterinary Medicine, Chungnam National University, Republic of Korea*

[P2.63]

Tracking the impact of COVID-19 vaccines on COVID-19-mortality with variant evolution and changing population immunity

Bette Liu*, Sandrine Stepien, Kristine Macartney, *National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, Australia*

[P2.64]

Declining Childhood Immunization in the Philippines (2012–2022): Research Priorities for Strengthening Systems and Reaching the Unreached

Kristal An Agrupis*, Michelle Ylade, *University of the Philippines Manila, The Philippines*

[P2.65]

Attenuation of foot-and-mouth disease virus using leader proteinase replacement and 3C mutation

Jong-Soo Lee^{*1}, Jong-Hyeon Park², ¹College of Veterinary Medicine, Chungnam National University, Republic of Korea, ²Center for Foot-and-Mouth Disease Vaccine Research, Animal and Plant Quarantine Agency, Republic of Korea

[P2.66]

Comparative genomics and evidence from challenge trials explain modest protective efficacy of current vaccines against *Lactococcus garvieae* in Australian Rainbow trout aquaculture

Oleksandra Rudenko^{*1,2}, Matt Landos³, James Fensham³, Mark White⁴, Andrew Barnes^{1,2}, ¹The University of Queensland, Australia, ²The University of Queensland Centre for Marine Science, Australia, ³Future Fisheries Veterinary Services, Australia, ⁴Tréidlia Biovet, Australia

[P2.67]

Delineating cell surface protein diversity to decipher host specificity, restrict host attachment and enable leptospiral vaccine development.

Nicholas Evans^{*1}, Abbie Hinds¹, Emily Johnson², Daniel Rigden², Stuart Carter¹, ¹University of Liverpool, Institute of Infection, Veterinary and Ecological Sciences, UK, ²University of Liverpool, Institute of Systems, Molecular and Integrative Biology, UK

[P2.68]

Development of a novel CVP providing broad protection against seasonal influenza viruses across multiple seasons.

Tomoko Honda¹, Sakiko Toyama¹, Fumihiko Yasui¹, Risa Kono¹, Ahmad Faisal Amiry¹, Ryusei Furusawa¹, Midori Nagai¹, Kyoko Tsukiyama-Kohara², Yasuyuki Gomi³, Takashi Kamishita⁴, Natsumi Kodake⁴, Takashi Miyazaki⁴, Michinori Kohara^{*1}, ¹Tokyo Metropolitan Institute of Medical Science, Japan, ²Kagoshima University, Japan, ³The Research Foundation for Microbial Diseases of the University of Osaka, Japan, ⁴Toko Yakuhin Kogyo Co., Ltd., Japan

[P2.69]

Supporting immunisation policy optimisation and evidence-based decision making: Capacity building of National Immunisation Technical Advisory Groups in the Asia Pacific region

Shu Chen¹, Ketaki Sharma^{1,2}, Sarah Sheridan¹, Yuanfei Huang¹, Xuanchen Tao¹, Ye Jin Joo¹, Louise Henaff³, Xiaojun Wang⁴, Vinod Bura⁵, Kristine Macartney^{*1,2}, ¹National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, Australia, ²The University of Sydney Faculty of Medicine and Health, Australia, ³World Health Organisation, Switzerland, ⁴World Health Organisation Western Pacific Region, The Philippines, ⁵World Health Organisation Southeast Asia Region, India

[P2.70]

Addressing immunization financing inefficiencies: policy reforms to reduce resource losses in Indonesia's decentralized system

Yohana Revi Imanita¹, Rizki Andini^{*1}, Ririn Ariani Dewi¹, Lili Nur Indah Sari¹, Saffana Mahmudah¹, Shabrina Mumtazah¹, Niken Widyastuti¹, Tetrwindu Hidayatullah¹, Atiek Anartati¹, Putri Herliana², Prima Yosephine³, Gertrudis Tandy³, Endang Budi Hastuti³, Devi Anisiska³, ¹Clinton Health Access Initiative, Indonesia, ²Clinton Health Access Initiative, USA, ³Ministry of Health of the Republic of Indonesia, Indonesia

[P2.71]

Unraveling the Cost of Reaching Zero-Dose Children: Financing Reforms for Immunization Equity in Indonesia

Saffana Hilmy Mahmudah¹, Lili Nur Indah Sari¹, Rizki Andini^{*1}, Yohana Revi Imanita¹, Shabrina Mumtazah¹, Niken Widyastuti¹, Tetrwindu Hidayatullah¹, Atiek Anartati¹, Putri Herliana², Prima Yosephine³, Gertrudis Tandy³, ¹Clinton Health Access Initiative, Indonesia, ²Clinton Health Access Initiative, USA, ³Ministry of Health of the Republic of Indonesia, Indonesia

[P2.72]

High-throughput measurement of mucosal neutralising antibodies against live SARS-CoV-2 virus

James Bazire¹, Giulia Dowgier¹, Agnieszka Hobbs¹, Phoebe Stevenson-Leggett¹, David Greenwood¹, Chris Cheshire¹, Richard Gilson², Steve Gamblin¹, Vincenzo Libri³, Bryan Williams³, Charles Swanton¹, Sonia Ghandi¹, David LV Bauer¹, Edward J Carr¹, Emma Wall¹, Mary Y Wu^{*1}, ¹The Francis Crick Institute, UK, ²University College London, UK, ³NIHR University College London Hospitals Biomedical Research Centre, UK

[P2.73]

Genetic mismatches with vaccine strains facilitate the persistence of influenza viruses during the COVID-19 pandemic

Ji-Yun Kim*, Da-Won Kim, Dong-Wook Lee, Ye-Jin Lee, Jung-Hoon Kwon, Kyungpook National University, College of Veterinary Medicine, Laboratory of Veterinary Microbiology, Republic of Korea

[P2.74]

Vaccine uptake among the youngest citizens of the Métis Nation of Ontario

Noel Tsui*^{1,2}, Abigail Simms^{1,2}, Shelley Cripps¹, Sarah Edwards^{1,2,3}, ¹Métis Nation of Ontario, Canada,²Institute for Clinical Evaluative Sciences, Canada,³University of Toronto, Canada

[P2.75]

Immune Pressure and SARS-CoV-2 Escape Potency: A Comparative Study of Different Vaccines and Immunization Regimens

Robert Andreato-Santos*^{1,2,3}, Jordan J. Clark^{4,3}, Jeremy S. Yong^{4,3}, Jéssica P. Farias^{5,6}, Jaime H. Amorim⁶, Luís C. S. Ferreira⁵, Florian Krammer^{4,3,7,8}, Luiz M. R. Janini^{9,10}, ¹Retrovirology Laboratory, Department of Microbiology, Immunology and Parasitology, Paulista School of Medicine, Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil., Brazil,²Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., USA,³Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA., USA,⁴Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., USA,⁵Department of Microbiology, Biomedical Sciences Institute, University of São Paulo, São Paulo, São Paulo, Brazil., Brazil,⁶Western Bahia Virology Institute, Center of Biological Sciences and Health, Federal University of Western Bahia, Barreiras, Bahia, Brazil., Brazil,⁷Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA., USA,⁸Ignaz Semmelweis Institute, Interuniversity Institute for Infection Research, Medical University of Vienna, Vienna, Austria., Austria,⁹Retrovirology Laboratory, Department of Microbiology, Immunology and Parasitology, Paulista School of Medicine, Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil., Brazil,¹⁰Department of Medicine, Division of Infectiology, Federal University of São Paulo, São Paulo, São Paulo, Brazil., Brazil

[P2.76]

Dynamic trends and shifting determinants of COVID-19 vaccine uptake in Nigeria

Oghenowede Eyawo*¹, Shenyi Pan², Patrick Oyibo³, Uchechukwu Ugoji⁴, ¹York University, Canada,²The University of British Columbia, Canada,³City University of London, UK,⁴Salem Clinic and Maternity, Nigeria

[P2.77]

Omicron-specific monovalent SARS-CoV-2 booster immunization can elicit de novo broadly neutralizing antibodies

Jordan Clark*^{1,2}, Raianna Fantin^{1,2}, Hallie Cohn^{1,2}, Deepika Jaiswal¹, Bailey Bozarth^{1,2}, Vishal Rao^{1,2}, Alesandro Civljak¹, Igor Lobo^{1,2}, Jessica Nardulli^{1,2}, Komal Srivastava^{1,2}, Jeremy Yong^{1,2}, Robert Andreato-Santos^{3,2,4}, Kaitlyn Bushfield^{1,2}, Edward Lee⁵, Gagandeep Singh^{1,2}, Steven Kleinstein^{6,7,8,9}, Florian Krammer^{10,2,10,11}, Viviana Simon^{12,2,13,14,15,16}, ¹Icahn School of Medicine at Mount Sinai Department of Microbiology, USA,²Icahn School of Medicine at Mount Sinai Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), New York, NY, USA,³Icahn School of Medicine at Mount Sinai Department of Microbiology, USA,⁴Retrovirology Laboratory, Department of Microbiology, Immunology and Parasitology, Paulista School of Medicine, Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil,⁵Yale School of Medicine Department of Laboratory Medicine, USA,⁶Yale University Program in Computational Biology and Biomedical Informatics, New Haven, CT, USA,⁷Yale School of Medicine Department of Immunobiology, USA,⁸Yale School of Medicine Department of Biomedical Informatics & Data Science, USA,⁹Yale University Department of Pathology, New Haven, CT, USA,¹⁰Icahn School of Medicine at Mount Sinai Department of Pathology, Molecular and Cell-Based Medicine, USA,¹¹Medical University of Vienna, Interuniversity Institute for Infection Research, Ignaz Semmelweis Institute, Vienna, Austria,¹²Icahn School of Medicine at Mount Sinai Lillian and Henry M Stratton-Hans Popper Department of Pathology Molecular and Cell-Based Medicine, USA,¹³Icahn School of Medicine at Mount Sinai Department of Pathology, Molecular and Cell-Based Medicine, New York, NY, USA,¹⁴Icahn School of Medicine at Mount Sinai Global Health and Emerging Pathogens Institute, New York, NY, USA,¹⁵Icahn School of Medicine at Mount Sinai Division of Infectious Diseases, Department of Medicine, New York, NY, USA,¹⁶Icahn School of Medicine at Mount Sinai Precision Immunology Institute New York, NY, USA

[P2.78]

Protective immunization using exosomes derived from macrophages infected with *Brucella abortus* 2308

Angel Oñate*, Vicente Arriagada, Gómez Leonardo, Universidad de Concepción, Chile

[P2.79]

Broad betacoronavirus immunity and SARS-CoV-2 protection induced by divergent spike-based nucleoside-modified vaccines

Anass Abbad^{*1,2}, Gagandeep Singh^{1,2}, Jordan J. Clark^{1,2}, Hyun Min Kang^{1,2}, Hiromi Muramatsu³, Sachchidanand Tiwari⁴, Lubbertus C F Mulder^{1,2,5}, Norbert Pardi⁶, Viviana Simon^{1,2,7,8}, Florian Krammer^{1,9,2,7}, ¹Icahn School of Medicine at Mount Sinai Department of Microbiology, USA, ²Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, USA, ³University of Pennsylvania Perelman School of Medicine; Department of Microbiology, USA, ⁴University of Pennsylvania Perelman School of Medicine; Department of Microbiology, USA, ⁵The Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, USA, ⁶University of Pennsylvania Perelman School of Medicine; Department of Microbiology, USA, ⁷Icahn School of Medicine at Mount Sinai Department of Pathology, USA, ⁸Icahn School of Medicine at Mount Sinai Department of Medicine Division of Infectious Diseases, USA, ⁹Medical University of Vienna, Austria

[P2.80]

Engineer E. coli heat-labile enterotoxin B subunit for mucosal adjuvant development

Sheng-Han Hsu¹, Da-You Xie², Cheng-Yen Tsai¹, Wei-Shuo Lin², Chu-Ya Wu³, Wen-Chun Liu⁴, Suh-Chin Wu², Shih-Che Sue^{*1}, ¹National Tsing Hua University Institute of Bioinformatics and Structural Biology, Taiwan, ²National Tsing Hua University Institute of Biotechnology, Taiwan, ³National Tsing Hua University Instrumentation Center, Taiwan, ⁴Academia Sinica Biomedical Translation Research Center, Taiwan

[P2.81]

Overcoming bottlenecks in vaccine manufacturing through reliable supply of high-quality molecules

Eli Keshavarz-Moore^{*}, University College London, UK

[P2.82]

Broadly cross-reactive B cell clones are derived de novo following sequential orthoflavivirus vaccination

Ruyue Liu^{*1}, Miles Benton², Florian Schmidt³, Andreas Wilm³, Eng Eong Ooi^{1,4,5,6}, Shirin Kalimuddin^{1,7}, October Sessions^{1,6,8}, ¹Duke-NUS Medical School Program in Emerging Infectious Diseases, Singapore, ²Oxford Nanopore Technologies, New Zealand, ³ImmunoScape Pte Ltd, Singapore, ⁴SingHealth Duke-NUS Academic Medical Centre Viral Research and Experimental Medicine Centre, Singapore, ⁵Singapore General Hospital Department of Translational Clinical Research, Singapore, ⁶National University of Singapore Saw Swee Hock School of Public Health, Singapore, ⁷Singapore General Hospital Department of Infectious Diseases, Singapore, ⁸National University of Singapore Department of Pharmacy, Singapore

[P2.83]

Development of a high-yield, molecular clamp stabilized, subunit vaccine with demonstrated protection against for H5N1 Highly Pathogenic Avian Influenza (HPAI)

Nicolas Tardiota^{*1}, Noushin Jaberolansar¹, Jake O'Donnell¹, Daniel Watterson², Connor Scott², Vivian Kienzle¹, Varsha Kommajosyula¹, Christina Henderson¹, Rhiannon Dalrymple¹, Diego Pilati¹, Marcelle van Mechele³, Mikaela Bell¹, Falko Apel³, Thomas Courant³, Nicolas Collin³, Keith Chappell^{1,2,4}, ¹The University of Queensland Australian Institute for Bioengineering and Nanotechnology, Australia, ²The University of Queensland The School of Chemistry and Molecular Biosciences, Australia, ³Vaccine Formulation Institute, Switzerland, ⁴The University of Queensland Australian Infectious Disease Research Centre, Australia

[P2.84]

The sero-prevalence and virulence determinants of *Klebsiella pneumoniae* isolated from urine in Outpatient unit: A 20-year collection from Taiwan as a herald for serotype vaccine selection

Esther Yip-Mei Liu^{*1}, Sheng-Kang Chiu², Jung-Chung Lin¹, Fu-Mei Lin³, Jia-Je Li¹, Yu-Kuo Tsai³, Ching-Hsun Wang¹, Feng-Yee Chang⁴, L. Kristopher Siu³, ¹Tri-Service General Hospital, National Defense Medical Center, Taiwan, ²Taipei Tzu Chi Hospital, Taiwan, ³National Health Research Institutes, Taiwan, ⁴Tri-Service General Hospital, National Defense Medical Center, Taiwan

[P2.85]

Development of Modified Vaccinia virus Ankara-based influenza vaccines for pandemic preparedness targeting hemagglutinin of selected influenza A virus subtypes

Gabriel Maiwald¹, Georgia Kalodimou², Veronika Pilchová¹, Sylvia Jany¹, Astrid Freudenstein¹, Marlowe Peter¹, Stephanie Riederer¹, Marina Kohn¹, Theresa Friebis¹, Satendra Kumar¹, Guus Rimmelzwaan³, Robert Fux¹, Gerd Sutter¹, Albert D.M.E. Osterhaus³, Alina Tscherne^{*1}, ¹Division of Virology, Department of Veterinary Sciences, LMU Munich, Oberschleißheim, Germany, ²Division of Virology, Department of Veterinary Sciences, LMU Munich, Oberschleißheim, Germany, ³Research Centre for Emerging Infections and Zoonoses, University of Veterinary Medicine, Hannover, Germany

[P2.86]

Mastitis After COVID-19 Vaccination: Collaborative Insights for Safer Immunisation

Aishwarya N Shetty^{1,2}, Pharmacovigilance Branch, Therapeutic Goods Administration Department of Health, Disability and Ageing³, Jim P Buttery^{*1,2,4,5}, Hazel J Clothier^{1,2,4}, ¹Epidemiology Informatics, Centre for Health Analytics, Melbourne Children's Campus, Melbourne, Victoria, Australia,²SAEFVIC, Murdoch Children's Research Institute, Melbourne, Victoria, Australia,³Therapeutic Goods Administration, Pharmacovigilance Branch, Australian Government Department of Health, Disability and Ageing, Canberra, Australian Capital Territory, Australia,⁴Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia,⁵Royal Children's Hospital, Melbourne, Victoria, Australia

[P2.87]

In Silico Optimization of Influenza Multi-Epitope Vaccines Using Protein Language Models and Bayesian Optimization

Hisahiro Ikari^{*1}, Seiya Kawano², Koichiro Yoshino², Tokiko Watanabe³, Yasuo Yoshioka³, Eiryu Kawakami¹, ¹Chiba University, Japan,²RIKEN Information R and D and Strategy Headquarters, Japan,³The University of Osaka Research Institute for Microbial Diseases, Japan

[P2.88]

Optimizing thermotolerant formulations of a live intranasal Newcastle disease virus (NDV)-based SARS-CoV-2 vaccine

Adam Abdeljawad^{*1}, Marta Boza¹, Tsoi Ying Lai¹, William B. Shea¹, Peter Palese^{1,2}, Weina Sun¹, Irene González-Domínguez¹, ¹Icahn School of Medicine at Mount Sinai Department of Microbiology, USA,²Icahn School of Medicine at Mount Sinai Department of Medicine, USA

[P2.89]

Development of an Oral Vaccine Platform Utilizing the Acid-Tolerant Microalgae, *Cyanidioschyzon merolae*

tsutomu omatsu^{*1}, Wei Liu^{1,2}, Hoai Nam Vu¹, Takayuki Fujiwara³, Shinya Miyagishima³, ¹Tokyo University of Agriculture and Technology, Japan,²National Institute of Infectious Diseases, Japan,³National Institute of Genetics, Japan

[P2.90]

Factors associated with misinformation beliefs and vaccine hesitancy, and their impact on COVID-19 mortality in Japan

Yuki Furuse^{*}, University of Tokyo, Japan

[P2.91]

Evaluation of the relationship between anti-RSV F antibody levels and RSV detection in nasopharyngeal swabs from children

Shiori Ueno^{*1}, Akira Ainai¹, Sho Miyamoto¹, Takeshi Arashiro^{1,2}, Kunihiro Oba^{3,4}, Kenichiro Takahashi⁵, Tadaki Suzuki¹, ¹Department of Infectious Disease Pathology, National Institute of Infectious Diseases, Japan Institute for Health Security, Japan,²Sanofi Vaccines Medical, Tokyo, Japan, Japan,³Department of Pediatrics, Showa General Hospital, Japan,⁴Department of Infection Control and Prevention, Showa General Hospital, Japan,⁵Department of Diagnostic Testing and Technology Research, National Institute of Infectious Diseases, Japan Institute for Health Security, Japan

[P2.92]

Pneumococcal Vaccination Strategies for Older Adults in Japan: A Systematic Review of PPSV23 RCTs and Recent Perspectives on Conjugate Vaccines

Hiroshi Moro^{*}, Nobumasa Aoki, Yuuki Bamba, Satoshi Shibata, Ikumi Yamagishi, Masahiro Ui, Hayato Tsuruma, Mariko Hakamata, Hideyuki Ogata, Hiromi Cho, Mizuho Sato, Toshiaki Kikuchi, Niigata University Faculty of Medicine Graduate School of Medical and Dental Science, Japan

[P2.93]

Evaluation of a DosR peptide-based subunit vaccine for protection against Tuberculosis using BALB/c mice

Manika Sharma^{*1}, Devanshu Kumar¹, Ayushi Kaur Bedi¹, Parul Bhatt¹, Anita Kamra Verma², Monika Sharma¹, Sadhna Sharma¹, ¹University of Delhi Miranda House, India,²University of Delhi Kirori Mal College, India

[P2.94]

Evaluating the Effectiveness and Cost-Effectiveness of One Health Vaccination Strategies

Luke O'Neill^{*}, The Pirbright Institute, UK, City University of London, UK

[P2.95]

Safety Assessment of a Sublingual Vaccine Formulated with Poly(I:C) Adjuvant and Influenza HA Antigen in Mice and Macaque Monkeys: Comparison with Intranasal Vaccine

Tetsuro Yamamoto^{1,2}, Fusako Mitsunaga^{3,4}, Atsushi Kotani^{*1,2}, Kazuki Tajima^{1,2}, Shin Nakamura^{3,4}, ¹Innovation Research Center, EPS Holdings, Inc, Japan,²Research Center, EPS Innovative Medicine Co., Ltd, Japan,³Intelligence & Technology Lab, Inc, Japan,⁴Biomedical Institute, NPO Primate Agora, Japan

[P2.96]

Integrative mapping of pre-existing influenza immune landscapes predicts vaccine response

Adriana Tomic^{*1}, Ivan Tomic², Stephanie Hao², Benjamin Lindsey³, Ya Jankey Jagne⁴, Katja Hoschler⁵, Adam Meijer⁶, Juan Manuel Carreño Quiroz⁷, Philip Meade⁷, Kaori Sano⁷, Chikondi Peno⁸, André Costa-Martins⁹, Debby Bogaert⁸, Beate Kampmann¹⁰, Helder Nakaya¹¹, Florian Krammer⁷, Thushan de Silva³, ¹Boston University, USA, ²Boston University, USA, ³The University of Sheffield, UK, ⁴Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Gambia, ⁵UK Health Security Agency, UK, ⁶National Institute for Public Health and the Environment, The Netherlands, ⁷Icahn School of Medicine at Mount Sinai Department of Microbiology, USA, ⁸The University of Edinburgh Centre for Inflammation Research, UK, ⁹University of São Paulo, Brazil, ¹⁰London School of Hygiene & Tropical Medicine, UK, ¹¹Brazil University, Brazil

[P2.97]

Development and application of customized pre-clinical animal models against emerging infectious disease

WEN-CHUN LIU*, Infectious Disease Core Facility, Biomedical Translation Research Center, Academia Sinica, Taiwan

[P2.98]

Evaluation of a broadly protective chimeric vaccine against type A foot-and-mouth disease viruses in East Asia

Sungho Shin*, Sang-Hyun Park, Seon Woo Kim, Yong Bin Kim, Hyein Park, Ji-In Kwon, Jaejo Kim, Jong-Hyeon Park, Animal and Plant Quarantine Agency, Republic of Korea

[P2.99]

Modeling mortality prediction in older adults with dementia receiving COVID-19 vaccination

Sara Kivity*, Maccabi Healthcare Services, Israel

[P2.100]

Development of an Intranasal COVID-19 Vaccine Using CpG Oligonucleotide as an Adjuvant

Kentaro Muranishi^{*1}, Mao Kinoshita², Keita Inoue², Junya Ohara², Toshihito Mihara², Kazuki Sudo², Ken J Ishii³, Teiji Sawa², Hiroyasu Ishikura¹, ¹Department of Emergency and Critical Care Medicine, Faculty of Medicine, Fukuoka University, Japan, ²Department of Anesthesiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Japan, ³Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Japan

[P2.101]

Research on the application of Kyushu University's proprietary lipid nanoparticle (LNP) formulation to cancer treatment.

naoya matsunaga*, National University Corporation Kyushu University, Japan

[P2.102]

Is our shield cracking? A comparative analysis of whole-cell and acellular pertussis vaccines and the resurgence of whooping cough in Poland.

Iwona Paradowska-Stankiewicz*, Agnieszka Rumik, Jakub Zbrzeźniak, Karolina Mrozowska-Nyckowska, National Institute of Public Health National Institute of Hygiene - National Research Institute, Poland

[P2.103]

Social Representations of Vaccination in the frame of biographical & family narratives – insights for communication and health interventions

Idalina Odziemczyk-Stawarz*, Jagiellonian University in Kraków, Poland

[P2.104]

Assessing the spatiotemporal variability in the impact of conjugate vaccines in France using LASSO and Bayesian meta-regression

Anabelle Wong^{*1,2}, Joshua L. Warren^{3,4}, Ulrike Gröttner^{5,6}, Sylvie Escolano⁷, Matthieu Domenech de Cellès¹, ¹Max-Planck-Institute for Infection Biology, Germany, ²Charité – Universitätsmedizin Berlin, Institute of Public Health, Germany, ³Yale School of Public Health, Department of Biostatistics, USA, ⁴Yale School of Public Health, Public Health Modeling Unit, USA, ⁵Charité – Universitätsmedizin Berlin, Institute of Biometry and Clinical Epidemiology, Germany, ⁶Charité – Universitätsmedizin Berlin, Berlin Institute of Health, Germany, ⁷French Institute of Health and Medical Research (Inserm) U1018: Centre for Research in Epidemiology and Population Health (CESP), High Dimensional Biostatistics Team, France

[P2.105]

Anti-neuraminidase and anti-HA stalk antibodies reduce the susceptibility to and infectivity of influenza A/H3N2 virus
Gregory Hoy^{1,2}, Thomas Cortier^{3,4,2}, Hannah E Maier¹, Guillermina Kuan^{5,6}, Roger Lopez^{5,7}, Necry Sanchez⁵, Sergio Ojeda⁵, Miguel Plazaola⁵, Daniel Stadlbauer⁸, Abigail Shotwell¹, Angel Balmaseda^{5,7}, Florian Krammer^{8,9,10}, Simon Cauchemez^{3,11}, Aubree Gordon^{*1,12}, ¹University of Michigan School of Public Health, USA, ²*co-first author, USA, ³Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, Université Paris Cité, France, ⁴Collège Doctoral, Sorbonne Université, France, ⁵Sustainable Sciences Institute, Nicaragua, ⁶Centro de Salud Sócrates Flores Vivas, Ministry of Health, Nicaragua, ⁷Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministry of Health, Nicaragua, ⁸Department of Microbiology, Icahn School of Medicine at Mount Sinai, USA, ⁹Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, USA, ¹⁰Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, USA, ¹¹*co-senior author, France, ¹²*co-senior author, USA

[P2.106]

A live attenuated SARS-CoV-2 vaccine constructed by dual inactivation of NSP16 and ORF3a
Ziwei Ye*, Shuofeng Yuan, Dong-Yan Jin, *The University of Hong Kong, Hong Kong*

[P3.01]

Humoral and cellular Immunity in response to in silico designed multi-epitope recombinant protein of Theileria annulata
Asadullah Abid, Ambreen Khalid, Muhammad Suleman, Haroon Akbar, Mian Abdul Hafeez, Jawaria Ali Khan, Muhammad Imran Rashid*, *University of Veterinary and Animal Sciences, Pakistan*

[P3.03]

Socio-Demographic and Behavioral Predictors of Multiple-Dose COVID-19 Vaccine Uptake Among Older Adults in Hong Kong: A Community-Based Cross-Sectional Study of The Generations Connect Project
Wan Jia Aaron He*, Runqi Yuan, Xinyu Zhang, Shao Yuna, Hoi Yan Ferrina Cheung, Siu Chee Sophia Chan, *The University of Hong Kong School of Public Health, Hong Kong*

[P3.04]

Influencing factors and trends in post-vaccination serologic testing completion rates among infants born to HBsAg-positive mothers in Guangdong Province, 2021–2023
Shuang Gao¹, Min Cai¹, Mengyang Su¹, Tianshuo Zhao², Xiyu Zhang², Sihui Zhang², Mingting Wang², Qingsong Xu², Yujie Cheng², Fuqiang Cui², Fenghua Liu¹, Tiancheng Xie^{*3}, ¹Department of Maternity Group Health, Guangdong Women and Children Hospital, Guangzhou, China, ²Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China, ³Peking University, China

[P3.05]

Impaired Immune Response and Memory Following SARS-CoV-2 Vaccination in Obese Mice
Nora Geissler^{*1}, Anna Schmid¹, Maria Orola-Taus¹, Erika Garner-Spitzer¹, Pia Gattlinger², Rudolf Valenta², Irma Schabussova¹, Aleksandra Inic-Kanada¹, Ursula Wiedemann¹, ¹Institute of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Vienna, Austria, ²Institute of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria, Austria

[P3.06]

Influenza-Associated Encephalitis/Encephalopathy in Children
GUNES BASKES*, KUBRA AYKAC, YASEMIN OZSUREKCI, *Hacettepe University School of Medicine, Turkey*

[P3.07]

Durability of protection from BNT162b2 and mRNA-1273 vaccines against SARS-CoV-2: a three-Year national cohort study in Qatar
Hiam Chemaitelly^{*1,2}, Houssein Ayoub³, Laith Abu-Raddad^{1,2}, ¹Weill Cornell Medicine - Qatar, Qatar, ²Weill Cornell Medicine, USA, ³Qatar University, Qatar

[P3.08]

Harmonizing safety assessment across the life cycle of new vaccines: sharing the five+ years experience of the Safety Platform for Emergency vACcines (SPEAC) project
Robert Chen^{*1}, Steve Black¹, Corry Dekker¹, Barbara Law¹, Marc Gurwith², Dale Nordenberg¹, Flor Munoz¹, Manu Chaudhary¹, Andy Stergachis¹, Esperanca Sevene¹, Wan-Ting Huang¹, Eileen Farnon¹, Miriam Sturkenboom¹, Rebecca Chandler³, ¹Brighton Collaboration, Task Force for Global Health, USA, ²Brighton Collaboration, Task Force for Global Health, USA, ³Coalition for Epidemic Preparedness Innovations UK Limited, UK

[P3.09]

The infant immune response to vaccination is seasonal

Laura Andrea Barrero Guevara^{1,2}, Sarah C. Kramer¹, Matthieu Domenech de Cellès¹, ¹Max-Planck-Institute for Infection Biology, Germany,²Charité University Hospital Berlin, Germany

[P3.10]

Multifaceted immunity against Sudan virus: CD4+ T cells as critical mediators

Lara Kelchtermans¹, Katrien Geerts¹, Winston Chiu¹, Carolien Dekeyser¹, Elias Broeckhoven¹, Johan Neyts^{1,2}, Yeranddy A. Alpizar¹, Kai Dallmeier¹, ¹KU Leuven Department of Microbiology Immunology and Transplantation, Belgium,²VirusBank Platform, Belgium

[P3.11]

Associations between common mental disorders and vaccination readiness against seasonal influenza and Covid-19 of chronically ill adult patients in primary care – a systematic review

Linda Sanftenberg¹, Laura Kraeker¹, Fabian Walter², Ioanna Tsiligianni^{3,4}, Izolde Bouloukaki⁵, Marco Roos², Jochen Gensichen¹, ¹Institute of General Practice and Family Medicine, LMU University Hospital, LMU Munich, Munich, Germany,²General Practice, Faculty of Medicine, University of Augsburg, Augsburg, Germany,³Clinic of Social and Family Medicine, Department of Social Medicine, Faculty of Medicine, University of Crete, Crete, Greece,⁴Department of Primary Care and Population Health, Medical School, University of Nicosia, Cyprus,⁵Clinic of Social and Family Medicine, Department of Social Medicine, Faculty of Medicine, University of Crete, Greece

[P3.12]

Yellow fever virus virion structure modulates antibody sensitivity and vaccine potency

Summa Bibby¹, James Jung¹, Yu Shang Low¹, Alberto Amarilla¹, Natalee Newton¹, Connor Scott¹, Jessica Balk², Yi Tian Ting², Morgan Freney¹, Benjamin Liang¹, Timothy Grant³, Fesséli Coulibaly², Paul Young¹, Roy Hall¹, Jody Hobson-Peters¹, Naphak Modhiran¹, Daniel Watterson¹, ¹The University of Queensland, Australia,²Monash University, Australia,³University of Wisconsin-Madison, USA

[P3.13]

HPV knowledge, awareness and vaccination attitude in sex and gender minorities: questionnaire-based study

Antonio Di Lorenzo^{*}, Paola Berardi, Andrea Martinelli, Claudia Palmieri, Francesco Paolo Bianchi, Silvio Tafuri, Pasquale Stefanizzi, University of Bari Interdisciplinary Department of Medicine, Italy

[P3.14]

Determinants of influenza vaccine uptake among rural populations in Alabama, a southeastern U.S. state

Salisa Westrick^{*}, Jingjing Qian, Oluchukwu Ezeala, Auburn University, USA

[P3.15]

IgG4 class-switch and Fc glycosylation patterns in adult and pediatric cohorts after three to five mRNA vaccine doses

Tamás Pongrácz¹, Ulrika Marking¹, Oscar Bladh¹, Katherina Aguilera¹, Matilda Berke^{1,2}, Sebastian Havervall¹, Nina Greilert-Norin¹, Jan Nouta³, Steinar Gijze³, Anna Wasynczuk³, Mikael Åberg⁴, Gestur Vidarsson^{5,6}, Manfred Wuhrer³, David Falck³, Youjia Zhong^{7,8}, Charlotte Thölin¹, ¹Karolinska Institute, Department of Clinical Sciences, Danderyd Hospital, Sweden,²National Bioinformatics Infrastructure, Sweden,³Leiden University Medical Center, Center for Proteomics and Metabolomics, The Netherlands,⁴Uppsala University, Department of Medical Sciences, Sweden,⁵Sanquin Research and Landsteiner Laboratory, Department of Experimental Immunohematology, The Netherlands,⁶Utrecht University, Department of Pharmaceutical Sciences, The Netherlands,⁷National University of Singapore, Yong Loo Lin School of Medicine, Department of Paediatrics, Singapore,⁸National University of Singapore, Khoo Teck Puat - National University Children's Medical Institute, Singapore

[P3.16]

Development of a Biofilm-Based Oral Vaccine Against *Nocardia seriolae* in Hybrid grouper (*Epinephelus fuscoguttatus* ♀ × *Epinephelus lanceolatus* ♂)

su FENG-JIE¹, Chen MEEI MEI², ¹National Kaohsiung University of Science and Technology, Taiwan,²National Taiwan University, Taiwan

[P3.17]

The optimization and purification of goose circovirus capsid protein expressed by *E. coli* expression system for vaccine development

Kun-Sheng Chen^{*}, Pei-Fang Hsieh, Poa-Chun Chang, Shan-Chia Ou, Ming-Kun Hsieh, National Chung Hsing University, Taiwan

[P3.18]

Associations between antibody titers in blood and respiratory mucosa, vaccinations and protection against subsequent SARS-CoV-2 and influenza A virus infections

Oscar Bladh^{*1}, Katherina Aguilera¹, Ulrika Marking^{1,2}, Nina Greilert¹, Ali Rihani³, Matilda Berkell^{4,1}, Jessica J Alm³, Mikael Åberg⁵, Charlotte Thålin¹, ¹Karolinska Institute Department of Clinical Sciences Danderyd Hospital, Sweden, ²Public Health Agency of Sweden, Sweden, ³Karolinska Institutet, Department of Microbiology, Tumor and Cell Biology, and National Pandemic Center, Sweden, ⁴Umeå University, Department of Plant Physiology, National Bioinformatics Infrastructure Sweden (NBIS), Science for Life Laboratory, Sweden, ⁵Uppsala University, Department of Medical Sciences, Clinical Chemistry and SciLifeLab Affinity Proteomics, Sweden

[P3.19]

Safety and Immunogenicity of mRNA Vaccine against Dengue Virus Serotype 2 with Modification of Potential Key Residues for Antibody-Dependent Enhancement

Han-Chung Wu^{*1,2}, Monika Kumari¹, Wen-Shan Li^{2,3}, ¹Institute of Cellular and Organismic Biology Academia Sinica, Taiwan, ²Academia Sinica Biomedical Translation Research Center, Taiwan, ³Institute of Chemistry Academia Sinica, Taiwan

[P3.20]

Amitripytiline potently neutralizes the replication of distinct SARS-CoV-2 Variants

Isabel Zydek^{*1}, Laura Thümmeler¹, Nadine Beckmann², Carolin Sehl², Matthias Soddemann², Peer Braß¹, Rabea Grüneberg¹, Carina Elsner³, Ulf Dittmer³, Oliver Witzke¹, Stephanie Kadow², Erich Gulbins², Katrin Anne Becker², Adalbert Krawczyk^{1,3}, ¹Department of Infectious Diseases, West German Centre of Infectious Diseases, University Medicine Essen, University Hospital Essen, University Duisburg, Germany, ²Institute of Molecular Biology, University Hospital Essen, University Duisburg Essen, 45147 Essen, Germany, ³Institute of Virology, University Hospital Essen, University Duisburg Essen, 45147 Essen, Germany, Germany

[P3.21]

Evaluation of a Self-Amplifying RNA Vaccine and Nanoerythrocyte-Based Delivery System for Enhanced Immune Response to SARS-CoV-2

Prerna Joshi^{*}, Prof. Shailja Singh, Prof. Anand Ranganathan, Jawaharlal Nehru University, India

[P3.22]

Incidence and associated factors of immunization stress-related reactions (ISRR) occurring within 15 minutes following HPV catch-up vaccination at a Japanese university

Tamami Ishikawa^{*1}, Yukari Isaka^{2,3}, Ai Hori^{2,3}, Hiromichi Suzuki^{2,3}, Mana Obata-Yasuoka², Shigeru Inoue¹, Masaki Machida^{1,4}, ¹Department of Preventive Medicine and Public Health, Tokyo Medical University, Japan, ²Institute of Medicine, University of Tsukuba, Japan, ³Institute of Medicine, Transborder Medical Research Center, University of Tsukuba, Japan, ⁴Department of Infection Prevention and Control, Tokyo Medical University Hospital, Japan

[P3.23]

A triplet circular mRNA vaccine formulation as a vaccine prototype against influenza A viruses

Sarat Lertjintanakit^{*1}, Chotiawat Seephetdee¹, Suwimon Manopwisedjaroen¹, Suradej Hongeng², Arunee Thitithanyanont¹, Patompon Wongtrakoongate¹, ¹Mahidol University Faculty of Science, Thailand, ²Mahidol University Faculty of Medicine Ramathibodi Hospital, Thailand

[P3.24]

Waning Hepatitis B Immunity in a Well-Vaccinated Hepatitis B Adolescent Cohort

Sarah Yao^{*}, Karen Nadua, Chia Yin Chong, Koh Cheng Thoon, Chee Fu Yung, Natalie Woon Hui Tan, Kai-Qian Kam, Peter Wong, Juliet Tan, Jiahui Li, KK Women's and Children's Hospital, Singapore

[P3.25]

Efficacy evaluation of an oral DNA vaccine against porcine epidemic diarrhea virus infection in pigs

Pei-Yin Wu^{*}, Frank Chang, Tzu-Pu Luo, Reber Genetics Co Ltd, Taiwan

[P3.26]

Investigation of the safety and protective efficacy of an attenuated and marker M. bovis-BoHV-1 combined vaccine in bovines

Sen Zhang^{*}, Aizhen Guo, Yingyu Chen, Huazhong Agricultural University, China

[P3.27]

Hypertonic intranasal vaccines gain nasal epithelia access to exert strong immunogenicity

Toshiro Hirai^{*1,2,3,4}, Soichiro Hashimoto³, Kazuo Takayama⁵, Yasuo Yoshioka^{1,2,3,4,6}, ¹Institute for Open and Transdisciplinary Research Initiatives, The University of Osaka, Japan, ²Research Institute for Microbial Diseases, The University of Osaka, Japan, ³Graduate School of Pharmaceutical Sciences, The University of Osaka, Japan, ⁴Center for Advanced Modalities and DDS, The University of Osaka, Japan, ⁵Center for iPS Cell Research and Application (CiRA), Kyoto University, Japan, ⁶The Research Foundation for Microbial Diseases of Osaka University, Japan

[P3.28]

Deconvolution of Cargo Delivery and Immunogenicity Following Intranasal Delivery of mRNA Lipid Nanoparticle Vaccines

Mai Vu^{*}, Devaki Pilapitiya, Andrew Kelly, Marios Koutsakos, Stephen Kent, Jennifer Juno, Hyon-Xhi Tan, Adam Wheatley, The University of Melbourne, Australia

[P3.29]

A malonic ester scaffold-driven design and development of potent ionizable lipids for functional mRNA delivery

Wen-Shan Li^{*1,2}, Jih-Liang Huang³, Han-Chung Wu^{2,4}, ¹Institute of Chemistry, Academia Sinica, Taipei, Taiwan, ²Biomedical Translation Research Center, Academia Sinica, Taipei, Taiwan, ³Biomedical Translation Research Center (BioTReC), Academia Sinica, Taipei, Taiwan, ⁴Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan

[P3.30]

The Impact of COVID-19 Vaccination on Long COVID Associated Healthcare Resource Utilisation (HCRU) and Costs in a Primary Care Setting in the UK

Jingyan Yang^{*1,2}, Kiran Rai³, Cale Harrison⁴, Rebecca Butfield⁴, David Gruben⁵, Hannah Gowman³, Rosie Hulme³, Isabel Jimenez³, Hannah Volkman¹, Jennifer Nguyen¹, ¹Pfizer Inc, USA, ²Columbia University, USA, ³Adelphi Real World, UK, ⁴Pfizer Limited, UK, ⁵Pfizer Inc Pennsylvania, USA

[P3.31]

Mucosal vaccination against SARS-CoV-2 using recombinant influenza viruses delivering self-assembling protein nanoparticles

Devaki Pilapitiya, Wen Shi Lee, Mai Vu, Marios Koutsakos, Jennifer Juno, Hyon-Xhi Tan, Adam Wheatley^{*}, The University of Melbourne, Australia

[P3.32]

Human papillomavirus vaccination coverage and risk-based cervical screening among middle-aged women in Hong Kong: A baseline analysis from DATAZONE Primary Healthcare Project

Sophia Siu Chee Chan^{*1}, Minjin Zhang¹, Yushen Zuo², Wanjia He¹, Derek Yee Tak Cheung², ¹The University of Hong Kong School of Public Health, Hong Kong, ²The University of Hong Kong School of Nursing, Hong Kong

[P3.33]

Interleukin-33 bridges TBK1-MyD88 signaling and CD8⁺ T cell activation in lipid nanoparticle mRNA vaccination

Kaiwen Liu^{*1}, Kouji Kobiyama¹, Naoko Satoh-Takayama², Tomoya Hayashi¹, Burcu Temizoz¹, Hideo Negishi¹, Asuka Tobuse¹, Mai Onaga¹, Areej Sakkour¹, Michelle Lee¹, Jalal Alshaweesh¹, Peter Katsikis³, Cevayir Coban¹, Ken Ishii¹, ¹The University of Tokyo Institute of Medical Science, Japan, ²RIKEN Center for Integrative Medical Sciences, Japan, ³Erasmus MC, The Netherlands

[P3.34]

Developing a mouse-adapted strain of cache valley virus aimed at use in immune-competent murine models for the validation of novel vaccine platforms.

Krisangel Lopez^{*1}, John Muller², Manette Tanelus², Dawn Auguste², Marissa Shrestha², Chad Mire³, Albert Auguste², ¹Virginia Polytechnic Institute and State University, USA, ²Virginia Polytechnic Institute and State University, USA, ³Foreign Arthropod Borne Animal Diseases Research Unit National Bio- and Agro-defense Facility, USA

[P3.35]

Characteristics of participants in a university-based HPV vaccine catch-up campaign in Japan

Yukari Isaka^{*1,2}, Masaki Machida³, Hiromichi Suzuki^{4,2}, Mana Obata-Yasuoka⁴, Mao Nakazawa⁵, Ai Hori^{4,2}, ¹Institute of Medicine, University of Tsukuba, Japan, ²Institute of Medicine, Transborder Medical Research Center, University of Tsukuba, Japan, ³Department of Preventive Medicine and Public Health, Tokyo Medical University, Japan, ⁴Institute of

[P3.36]

Influenza epidemiology, severity and importance of vaccination post-lifting of pandemic public health measures.

Chee Fu Yung^{*1,2,3}, Chia Yin Chong¹, Natalie Tan¹, Xue Fen Seah¹, Rina Ong¹, Sarah Yao¹, Christopher Seow¹, Karen Nadua Donceras¹, Kai Qian Kam¹, Koh Cheng Thoon¹, Jia Hui Li¹, ¹KK Women's and Children's Hospital, Singapore, ²Duke-NUS Medical School, Singapore, ³Lee Kong Chian School of Medicine, Singapore

[P3.37]

Development of the immunoglobulin Y against waterfowl parvovirus infections

Yu-Chen Hsu^{*1}, Kuang-Po Li², Hua Yen¹, Shan-Chia Ou¹, ¹Graduate Institute of Microbiology and Public Health, College of Veterinary Medicine, National Chung Hsing University, Taiwan, ²Graduate Institute of Veterinary Pathobiology, College of Veterinary Medicine, National Chung Hsing University, Taiwan

[P3.38]

Broadly cross-reactive immunity elicited by a HERV-enveloped recombinant baculovirus DNA influenza vaccine

Hee Jung Lee^{*1}, Youngjik Lee¹, Sehyun Kim^{1,2}, Doyoung Yoon¹, Young Bong Kim^{1,2}, ¹Konkuk University, Republic of Korea, ²KR Biotech, Republic of Korea

[P3.39]

Prevention of RSV bronchiolitis in infants by maternal vaccination or nirvesimab in neonates: what do mothers choose?

Salomé Azéroul¹, Paul Rey¹, Caroline Charlier², Odile Launay², Olivia Anselem^{*1}, ¹Port-Royal Maternity, France, ²Hospital Cochin, France

[P3.40]

Understanding the role of antibodies in vaccine-induced protection through monoclonal antibody SARS-CoV-2 prophylaxis

Eva Stadler^{*1}, Martin T. Burgess², Timothy Schlub³, Shanchita R. Khan¹, Khai Li Chai⁴, Zoe K. McQuilten⁴, Erica M. Wood⁴, Mark N. Polizzotto⁵, Stephen J. Kent⁶, Deborah Cromer¹, Miles P. Davenport¹, David S. Khoury¹, ¹The Kirby Institute, Australia, ²University of New South Wales, Australia, ³The University of Sydney Faculty of Medicine and Health, Australia, ⁴Monash University, Australia, ⁵Australian National University, Australia, ⁶The Peter Doherty Institute for Infection and Immunity, Australia

[P3.41]

Characterization of 3 nt-deletion chikungunya virus for the development of novel vaccines

Rie Doi^{*1,2}, Simon Goto^{1,2}, Fumiyo Ogawa^{1,2}, Akira Takada^{1,2}, Daisuke Motooka³, Youichi Suzuki⁴, Takashi Nakano⁴, Hiroataka Ebina^{1,2}, ¹Virus Vaccine group, BIKEN Innovative Vaccine Research Alliance Laboratories, Institute for Open and Transdisciplinary Research Initiatives, University of Osaka, Japan, ²The Research Foundation for Microbial Diseases of Osaka University, Japan, ³Bioinformatics Center NGS core facility, Research Institute for Microbial Diseases, University of Osaka, Japan, ⁴Department of Microbiology and Infection Control, Faculty of Medicine, Osaka Medical and Pharmaceutical University, Japan

[P3.42]

Innovative mucosal adjuvant development using heat-killed *Escherichia coli*

Gao Peng^{*1}, Hideo Negishi^{1,2}, Mizuki Yamamoto³, Ryuta Uraki⁴, Maki Kiso⁴, Mutsumi Ito⁴, Mizuho Wakayama⁵, Chiaki Tomimoto⁵, Ken Ishii^{6,2}, Yoshihiro Kawaoka⁴, Reiko Shinkura¹, ¹Laboratory of Immunology and Infection Control, Institute for Quantitative Biosciences, The University of Tokyo, Japan, ²Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Japan, ³Research Center for Asian Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Japan, ⁴Division of Virology, Institute of Medical Science, The University of Tokyo, Japan, ⁵Noster Inc., Japan, ⁶Division of Vaccine Science, Department of Infection and Immunity, The Institute of Medical Science (IMSUT), The University of Tokyo, Japan

[P3.43]

Extending the GRADE Evidence-to-Decision framework for assessing combination respiratory virus vaccines

Clayton Chiu^{*1,2}, Alexis Pillsbury^{1,2}, Jeff (Zhicheng) Wang^{1,2}, Helen Quinn^{1,2}, Kristine Macartney^{1,2}, ¹National Centre for Immunisation Research and Surveillance, Australia, Australia, ²Faculty of Medicine and Health, The University of Sydney, Australia, Australia

[P3.44]

Efficacy evaluation of a quadrivalent inactivated vaccine against *Glaesserella parasuis* serovar 4

Chia-Hung Yen^{*1,2,3}, Yu-An Tai^{1,2,3}, Yi-Cheng Li^{1,2}, Hsuan-Po Chen^{1,2}, Ni-Jyun Ke¹, Chiung-I Huang¹, Chao-Nan Lin^{1,2,3}, Ming-Tang Chiou^{1,2,3}, Wei-Hao Lin^{1,2,3}, ¹Department of Veterinary Medicine, National Pingtung University of Science and Technology, Taiwan, ²Animal Disease Diagnostic Center, National Pingtung University of Science and Technology, Taiwan, ³Sustainable Swine Research Center, National Pingtung University of Science and Technology, Taiwan

[P3.45]

Factors associated with hepatitis B vaccine nonresponse in infants of hepatitis B surface antigen positive mothers: Analysis of a national prevention program of Korea, 2002-2021

Moran Ki^{*1}, Byung-Woo Kim¹, Naradi Baduge¹, Jong-Hyun Kim², ¹Department of Public Health & AI, Graduate School of Cancer Science and Policy, National Cancer Center, Republic of Korea, ²Division of Pediatric Infectious Diseases, Department of Pediatrics, St Vincent's Hospital, The Catholic University of Korea, Republic of Korea

[P3.46]

The role of Fc conjugation to F1 antigen in improving the effectiveness of mRNA-LNP vaccines against the *Yersinia Pestis* bacterium

Shani Benarroch^{*1}, Uri Elia², Inbal Hazan-Halevy³, Ronit Rosenfeld², Tal Noy-Porat², Hila Cohen², Erez Bar-Haim², Yinon Levy², Meir Goldsmith³, Ofer Cohen², Emanuelle Mamroud², Dan Peer³, ¹Tel Aviv University The George S Wise Faculty of Life Sciences, Israel, ²Israel Institute for Biological Research, Israel, ³Tel Aviv University The George S Wise Faculty of Life Sciences, Israel

[P3.47]

An insect-specific flavivirus-based chimeric vaccine provides durable and broadly protective immunity in murine models

Manette Tanelus^{*}, John Muller, Dawn Auguste, Krisangel López, Albert Auguste, Virginia Polytechnic Institute and State University, USA

[P3.48]

Are Vaccine Mandates Coercive?

Maxwell Smith^{*}, Western University, Canada

[P3.49]

Impact of COVID-19 vaccination on reducing prolonged hospitalization risk in severe COVID-19 patients with invasive fungal infections: The modifying role of diabetes

Thang Dao Van^{*1,2}, Truong Cao Van³, Hung Than Manh⁴, Tuyen Duong Van⁵, ¹International Ph.D. Program in Medicine, College of Medicine, Taipei Medical University, Taiwan, ²Department of Infectious Diseases, 103 Military Hospital, Vietnam, ³Institute of Military Preventive Medicine, Vietnam, ⁴Emergency Department, National Hospital of Tropical Diseases, Vietnam, ⁵School of Nutrition and Health Sciences, Taipei Medical University, Taiwan

[P3.50]

Inequalities in vaccination before and after COVID-19: spatio-temporal modelling of zero-dose children

Nieves Derqui^{*}, Nicholas C Grassly, Katy A M Gaythorpe, Margarita Pons-Salort, MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, UK

[P3.51]

Gut Microbiota Recovery Predicts Vaccine-Induced Protection Against African Swine Fever Virus in Pigs

Yeonsu Oh¹, Young-Seung Ko², Sung-Hyun Moon², Myung Jo You², Seung-Hun Lee³, Hyangju Kang⁴, Ho-Seong Cho^{*2}, ¹College of Veterinary Medicine and Institute of Veterinary Science, Kangwon National University, Chuncheon 24341, Republic of Korea, ²College of Veterinary Medicine and Bio-Safety Research Institute, Jeonbuk National University, Iksan 54596, Republic of Korea, ³College of Veterinary Medicine, Chungbuk National University, Cheongju 28644, Republic of Korea, ⁴BioApplications Inc., Pohang Techno Park Complex, 394 Jigok-ro, Pohang 37668, Republic of Korea

[P3.52]

Co-designing adolescent vaccine uptake strategies with youth through a Nudgeathon

Bing Wang^{*1,2}, Prabha Andraweera^{1,2}, Mark McMillan^{1,2}, Ivo Vlaev³, Jason Ong^{4,5}, Louise Flood⁶, Noel Lally⁶, Helen Marshall^{1,2}, ¹The University of Adelaide, Australia, ²Women's and Children's Health Network, Adelaide, Australia, ³University of Warwick - Warwick Business School, UK, ⁴Monash University, Australia, ⁵London School of Hygiene & Tropical Medicine, UK, ⁶SA Health, Australia

[P3.53]

Study of an inactivated gE-deleted marker vaccine against Bovine alphaherpesvirus 1 (BoAHV-1) in water Buffalo.
Cecilia Righi¹, Alessandra Martucciello², Francesco Grandoni³, Giovanna De Matteis³, Giovanna Cappelli², Monica Giammaroli¹, Eleonora Scoccia¹, Carlo Grassi², Giorgio Galiero², Michela Pela¹, Esterina De Carlo², Stefano Petri¹,
¹National Reference Centre for Infectious Bovine Rhinotracheitis (IBR), Istituto Zooprofilattico Sperimentale Umbria-Marche, "Togo Rosati," 06126 Perugia, Italy., Italy,²National Reference Centre for Hygiene and Technology of Breeding and Buffalo Production, Istituto Zooprofilattico Sperimentale del Mezzogiorno, 84131 Salerno, Italy., Italy,³Research Centre for Animal Production and Aquaculture, Monterotondo, 00015 Rome, Italy., Italy

[P3.54]

Comparative analysis of mRNA and self-amplifying RNA vaccines targeting human norovirus GII.4 in mice
Seo Yun Hong^{1,2}, Seo-Yeon Hwang³, Haewon Jung³, Han Young Seo³, Jong-Won Oh^{1,2,3}, ¹RpexBio Inc., Yonsei University Engineering Park B140, Seoul 03722, Republic of Korea,²Graduate Program in Bio-industrial Engineering, Yonsei University, Seoul 03722, Republic of Korea,³Department of Biotechnology, Yonsei University, Seoul 03722, Republic of Korea

[P3.55]

Prevalence and Serotype Distribution of Nasopharyngeal Carriage of Streptococcus Pneumoniae in Vietnam: A Systematic Review and Meta-analysis

Kristine Macartney¹, Xuanchen Tao¹, Ketaki Sharma¹, Catherine King¹, Toan Trong Nguyen², Thu-Anh Nguyen³, Huyen Dang³, Linh Duong³, Mai Duong², Phoebe Williams¹, Sanjay Jayasinghe¹, Beth Temple⁴, Kim Mulholland⁵, ¹National Centre for Immunisation Research and Surveillance, Australia,²Pasteur Institute of Ho Chi Minh City, Vietnam,³The University of Sydney Vietnam Institute, Vietnam,⁴Menzies School of Health Research, Australia,⁵Murdoch Children's Research Institute, Australia

[P3.56]

Structure-guided design of SARS-CoV-2 spike protein with concealed receptor-binding domain to enhance cross-reactivity against variants

Takuya Hemmi^{1,2}, Saya Moriyama², Akira Ainai², Sho Miyamoto², Satoru Nagatoishi³, Hisano Yajima¹, Rin Shirota¹, Shiori Ueno², Kei Asayama², Kouhei Tsumoto³, Yukihiro Sugita¹, Takeshi Noda¹, Yoshimasa Takahashi², Tadaki Suzuki², Takao Hashiguchi¹, ¹Kyoto University, Japan,²National Institute of Infectious Diseases, Japan,³The University of Tokyo, Japan

[P3.57]

HERV-enveloped recombinant baculovirus DNA vaccine (AcherV-H5-ConA) induces broad cross-reactive immunity against influenza viruses

Hee-Jung Lee¹, Youngjik Lee¹, Doyoung Yoon¹, Sehyun Kim², Young Bong Kim^{1,2}, ¹Konkuk University, Republic of Korea,²KR BioTech, Republic of Korea

[P3.58]

Molecular characteristics of enolase, its functional role in Haemaphysalis longicornis survival, and its potential as a vaccine candidate for efficient tick control

Myung-Jo You¹, Md Samiul Haque², Sung-Hyun Moon³, Ho-Seong Cho³, Yeonsu Oh⁴, Seung-Hun Lee⁵, Hyangju Kang⁶,
¹Laboratory of Veterinary Parasitology, College of Veterinary Medicine and Bio-Safety Research Center, Jeonbuk National University, Iksan 54596., Republic of Korea,²Laboratory of Veterinary Parasitology, College of Veterinary Medicine and Bio-Safety Research Center, Jeonbuk National University, Iksan 54596., Republic of Korea,³College of Veterinary Medicine and Bio-Safety Research Institute, Jeonbuk National University, Iksan 54596., Republic of Korea,⁴College of Veterinary Medicine and Institute of Veterinary Science, Kangwon National University, Chuncheon, Republic of Korea,⁵College of Veterinary Medicine, Chungbuk National University, Cheongju 28644., Republic of Korea,⁶BioApplications Inc., Pohang Techno Park Complex, 394 Jigok-ro, Pohang 37668, Republic of Korea

[P3.59]

Computational Prediction of the Neutralization Breadth of Convergent Antibodies Targeting SARS-CoV-2 Variants
Hisham Dokainish¹, Hiroaki Sasaki¹, Ryutaro Kotaki^{2,1}, Taishi Onodera¹, Saya Moriyama¹, Yoshimasa Takahashi¹, ¹Research Center for Vaccine Development, Institute of Infectious Diseases, Japan Institute for Health Security, Japan,²The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), The University of Tokyo, Japan

[P3.60]

Development of new method for the evaluation of the safety and quality control of SARS-CoV-2 mRNA vaccine
Kou Hiraga^{*}, Haruka Momose, Wakako Kuribayashi, Mami Uemura, Sayuri Sakuragi, Kiyoko Nojima, Mieko Ishii, Keiko Imai, Junichi Maeyama, Yohei Seki, Madoka Kuramitsu, Takuo Mizukami, Center for Next-Generation Biologics Research, National Institute of Infectious Diseases, Japan Institute for Health Security, Japan

[P3.61]

Comprehensive mapping and sorting of extracellular particles, viruses and mRNA vaccines

Shuntaro Shimizu^{1,2,3,4}, Tomoya Hayashi^{5,2,3}, Kouji Kobiyama^{5,2,3}, Hideo Negishi^{5,2,3}, Burcu Temizoz^{5,2,3}, Cevayir Coban^{2,3,6}, Ken Ishii^{1,2,3}, ¹Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo (IMSUT), Japan, ²International Vaccine Design Center, IMSUT, Japan, ³The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), The University of Tokyo, Japan, ⁴Department of Chemistry, Chemical Engineering & Life Science, Yokohama National University, Japan, ⁵Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo (IMSUT), Japan, ⁶Division of Malaria Immunology, Department of Microbiology and Immunology, IMSUT, Japan

[P3.62]

Stalling Protection: A Decade of Regional Declines in Measles Vaccination Coverage in the Philippines

Michelle Ylade*, Kristal An Agrupis, University of the Philippines Manila, The Philippines

[P3.63]

Laboratory-based confirmation of clinically suspected mumps cases and viral etiological investigation of mumps virus-undetected parotid swelling cases in Japan using target capture-based next-generation sequencing: insights for the introduction of routine mumps vaccination

Yumani Kuba^{*1}, Nobuhiro Takemae¹, Manami Negoro², Manami Nakashita³, Hajime Kamiya^{4,5}, Shigeru Suga², Kiyosu Taniguchi², Tsutomu Kageyama¹, ¹Department of Diagnostic Testing and Technology Research, National Institute of Infectious Diseases, Japan Institute of Health and Security, Japan, ²Department of Pediatrics, National Hospital Organization Mie National Hospital, Japan, ³Center for Public Health Action in Applied Epidemiology, National Institute of Infectious Diseases, Japan Institute of Health and Security, Japan, ⁴Department of Public Health, Occupational Medicine, and Applied Epidemiology, Graduate School of Medicine, Mie University, Japan, ⁵Center for Infectious Disease Epidemiology, National Institute of Infectious Diseases, Japan Institute for Health Security, Japan

[P3.64]

The glycosylation of antibodies specific to respiratory viruses influences pro-inflammatory cytokine responses.

Wenjun Wang¹, Annemarie Spigt¹, Shirin Mostert¹, David Falck¹, Steven de Taeye², Gert-Jan Braunstahl³, Gerdien Tramper³, Manfred Wuhrer¹, Hermelijn Smits¹, Willianne Hoepel^{*1}, ¹Leiden University Medical Center, The Netherlands, ²Amsterdam UMC Location AMC, The Netherlands, ³Franciscus Gasthuis en Vlietland, The Netherlands

[P3.65]

Immunogenicity of 8th booster doses of SARS-CoV-2 JN.1 monovalent mRNA vaccine and recombinant spike protein with Matrix-M adjuvant vaccine against SARS-CoV-2 omicron sub-variants and evaluation of post-booster safety profile.

Yohei Seki¹, Kiyoko Nojima¹, Sayuri Sakuragi¹, Haruka Momose¹, Wakako Kuribayashi¹, Kei Miyakawa², Shutoku Matsuyama³, Kou Hiraga¹, Hideki Hasegawa², Isao Hamaguchi¹, Yasuo Yoshihara⁴, Takuo Mizukami^{*1}, ¹Center for Next-generation Biologics Research, National Institute of Infectious Diseases, Japan Institute for Health Security, Japan, ²Influenza Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Japan, ³Department of Respiratory Viruses, National Institute of Infectious Diseases, Japan Institute for Health Security, Japan, ⁴National Hospital Organization Murayama Medical Center, Japan

[P3.66]

Inhalable RNA-scaffold protein vaccine platform

Shuk-Kwan Cheung^{*1,2}, Chun-Kit Yuen^{1,2}, Kin-Hang Kok^{1,2}, ¹Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, ²Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong

[P3.67]

Funding for finding Zero-Dose children in Indonesia: how immunization programs can foster Gender Equity and Social Inclusion (GESI)

Rizki Andini^{*1}, Lili Nur Indah Sari¹, Yohana Revi Imanita¹, Saffana Hilmy Mahmudah¹, Shabrina Mumtazah¹, Atiek Anartati¹, Niken Widayastuti¹, Prima Yosephine², Gertrudis Tandy², Vivi Voronika², Edy Haryanto², ¹Clinton Health Access Initiative, Indonesia, ²Ministry of Health of the Republic of Indonesia, Indonesia

[P3.68]

Policy recommendations to strengthen health systems' vaccine literacy for equitable immunization of newly arrived migrants: the ActoVax4NAM project

Caterina Ferrari^{*1,2}, Maria Laura Russo¹, Pania Karnaki³, Giulia Marchetti², Maria Elena Tosti², Maurizio Marceca¹, Silvia Declich², ¹University of Rome La Sapienza, Italy, ²National Institute of Health, Italy, ³Prolepsis Institute, Greece

[P3.69]

Decentralized governance and immunization sustainability: subnational financing insights from Indonesia's Post-Gavi transition (2019-2024 period)

Yohana Revi Imanita¹, Lili Nur Indah Sari¹, Rizki Andini¹, Saffana Mahmudah¹, Shabrina Mumtazah¹, Niken Widyastuti¹, Atiek Anartati¹, Hashta Meyta², Septianita Hastuti², Prima Yosephine², ¹Clinton Health Access Initiative, Indonesia,²Ministry of Health of the Republic of Indonesia, Indonesia

[P3.70]

Novel engineered catcher enables hetero variant display of SARS-CoV-2 RBDs on capsid virus-like particles for increased broadness of protection

Anna Kathrine Okholm¹, Panagiota Panagopoulou², Louise Goksør³, Alexander P. Underwood^{4,5}, Jens Bukh^{4,5}, W. A. de Jongh³, Adam F. S. Sander^{2,3}, ¹Centre for Translational Medicine and Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, Denmark,²Centre for Translational Medicine and Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, Denmark,³AdaptVac Aps, Copenhagen, Denmark, Denmark,⁴Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Denmark,⁵Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark, Denmark

[P3.71]

Preclinical evaluation of a universal influenza vaccine candidate based on nucleoside-modified mRNA lipid nanoparticles coding for chimeric hemagglutinins

Robert Hoelzl^{1,2}, Norbert Pardi³, Hiromi Muramatsu³, Eduard Puente^{1,2}, Florian Krammer^{1,2,4,5}, ¹Icahn School of Medicine at Mount Sinai Department of Microbiology, USA,²Icahn School of Medicine at Mount Sinai, Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), USA,³University of Pennsylvania Department of Microbiology, USA,⁴Medical University of Vienna, Vienna, Austria, Ignaz Semmelweis Institute, Interuniversity Institute for Infection Research, Austria,⁵Icahn School of Medicine at Mount Sinai, New York, NY, USA, Department of Pathology, Molecular and Cell-Based Medicine, USA

[P3.72]

Resurgence of pertussis in South Korea: focusing clinical characteristics of pediatric patients with pertussis

Yoonsun Yoon¹, Ji Young Park², Young-June Choi³, In-Kyung Choi², Yun-Kyung Kim², ¹Korea University Guro Hospital Department of Pediatrics, Republic of Korea,²Korea University Ansan Hospital Department of Pediatrics, Republic of Korea,³Korea University Anam Hospital Department of Pediatrics, Republic of Korea

[P3.73]

Vaccine uptake among Métis Nation of Ontario citizens aged 65 years and older

Abigail Simms^{1,2}, Noel Tsui^{1,2}, Shelley Cripps¹, Sarah Edwards^{1,2}, ¹Métis Nation of Ontario, Canada,²Institute for Clinical Evaluative Sciences, Canada

[P3.74]

Development of multi-epitope vaccines against *Acinetobacter baumannii*, a nosocomial bacterial pathogen

Jieh-Juen Yu*, Sean Jeffreys, Jadelynn Aki, Nicolas Prather, The University of Texas at San Antonio, USA

[P3.75]

Motivating Factors among LGBTQ+ Individuals for the Uptake of a Forthcoming HIV Vaccine: Recommendations for Enhancing Preparedness

Kendra I. Lewis^{1,2}, Davin Goulbourne², Andie Weiser-Schlesinger², Catherine Miller², Perry N. Halkitis^{1,2}, Kristen D. Krause^{1,2}, ¹Rutgers School of Public Health, USA,²Center for Health Identity Behavior and Prevention Studies, USA

[P3.76]

Peptones reduce serum dependency in vaccine manufacturing

Syed Muaz Khalil*, Wen-Yang Tsai, Bilal Mughal, Ashwin Gurunathan, Saranya Chitturi, Stacy Holdread, James Brooks, Thermo Fisher Scientific, Hunt Valley, MD, USA

[P3.77]

Prophylactic and Therapeutic Efficacy of a Live Attenuated HSV-1 Vaccine Candidate for Protection against HSV-2

Jonathan C. Ellis-Smith¹, Matthew D. Irwin¹, Jonathan D. Joyce¹, Andrea S. Bertke¹, Edward Gershburg², ¹Virginia Tech, Blacksburg, VA, USA,²Rational Vaccines Inc., USA

[P3.78]

Strategies to augment immunogenicity of small viral antigens: interplay of multimerisation and CD4 T cell help

Jennifer Juno*, Hyon-Xhi Tan, Mai Vu, Kathleen Wragg, Lydia Murdiyarso, Devaki Pilapitiya, Ming Zheng, Adam Wheatley, The Peter Doherty Institute for Infection and Immunity, Australia

[P3.79]

Road map for veterinary vaccine research and development – stage gate and technology readiness level

Mingmin Liao*, Andrew Van Kessel¹, Georges Thiry², Trina Racine¹, Paul Hodgson¹, Jose Rodriguez¹, ¹Vaccine and Infectious Disease Organization, University of Saskatchewan, Canada, ²Senegues Consult, France

[P3.80]

Application of 450 nm Blue Light-Emitting Diode on Growth Promotion, Cannibalism Reduction, and Immune Enhancement in Hybrid Grouper Larvae

Yung-Song Wang¹, Min-Luen Tsai², Yijui Hsieh³, Li-Xi Xu², Yi-Hsuan Chen⁴, FENG-JIE SU*⁴, ¹National Taiwan University, Taiwan, ²National Kaohsiung University of Science and Technology, Taiwan, ³Penghu Fisheries Biology Research center M.O.A, Taiwan, ⁴National Kaohsiung University of Science and Technology, Taiwan

[P3.81]

An attenuated vaccinia virus vaccine carrying the SARS-CoV-2 S gene confers protective immunity to prevent infiltration of lymphocytes and macrophages in the lung without antibody-dependent enhancement after alpha and beta variant infection in rhesus macaques

Yasushi Itoh*¹, Cong Thanh Nguyen¹, Fumihiko Yasui², Hirohito Ishigaki¹, Kenichi Otaki¹, Koji Ishii³, Tomoe Kusayanagi⁴, Yoshiki Yagi⁴, Michinori Kohara², ¹Shiga University of Medical Science, Japan, ²Tokyo Metropolitan Institute of Medical Science, Japan, ³National Institute of Infectious Diseases, Japan, ⁴Nobelpharma Co Ltd, Japan

[P3.82]

Preclinical evaluation of mRNA and ISVAc vaccine technologies for emerging arboviruses

Wilson Nguyen¹, Abigail Cox¹, Agnes Carolin¹, Bing Tang¹, Kexin Yan¹, Romain Tropee², Jonathan Peters², Nigel McMillan³, Lucy Wales-Earl³, Jody Hobson-Peters⁴, Jessica Harrison⁵, Mikaela Bell⁵, Alexander Khromykh⁵, Andreas Suhrbier¹, Daniel Rawle*¹, ¹QIMR Berghofer, Australia, ²Southern RNA, Australia, ³Institute for Biomedicine and Glycomics, Griffith University, Australia, ⁴School of Chemistry and Molecular Biosciences, The University of Queensland, Australia, ⁵School of Chemistry and Molecular Biosciences, The University of Queensland, Australia

[P3.83]

Alcaligenes lipid A acts as a sublingual adjuvant to augment protective immune responses both in the respiratory and gastrointestinal tracts

Yuki Hirayama*^{1,2}, Ken Yoshii¹, Zilai Liu^{1,2}, Atsushi Shimoyama^{3,4,5}, Keigo Iemitsu^{1,6}, Koji Hosomi^{1,7}, Hiroshi Kiyono^{8,9,10,11,12}, Koichi Fukase^{3,4,5}, Jun Kunisawa^{1,2,3,6,13,14,15,16}, ¹Laboratory of Vaccine Materials and Laboratory of Gut Environmental System, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health, and Nutrition (NIBN), Japan, ²Graduate School of Pharmaceutical Sciences, The university of Osaka, Japan, ³Graduate School of Science, The university of Osaka, Japan, ⁴Institute for Radiation Sciences, The University of Osaka, Japan, ⁵Center for Advanced Modalities and DDS, Japan, ⁶Graduate School of Medicine, The university of Osaka, Japan, ⁷Graduate School of Veterinary Science, Osaka Metropolitan University, Japan, ⁸Division of Gastroenterology, Department of Medicine, University of California San Diego (UCSD) School of Medicine, UC San Diego, USA, ⁹Chiba University (CU)–UCSD Center for Mucosal Immunology, Allergy and Vaccines (cMAV), UC San Diego School of Medicine, UC San Diego, USA, ¹⁰Future Medicine Education and Research Organization, Chiba University, Japan, ¹¹Department of Human Mucosal Vaccinology, Chiba University Hospital, Japan, ¹²Synergy Institute for Futuristic Mucosal Vaccine Research and Development (cSIMVa), Chiba University, Japan, ¹³International Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo, Japan, ¹⁴Graduate School of Medicine, Kobe University, Japan, ¹⁵Graduate School of Dentistry, The university of Osaka, Japan, ¹⁶Research Organization for Nano and Life Innovation, Waseda University, Japan

[P3.84]

Fabrication and In Vivo Characterization of a Penta-Component Microneedle Patch Platform for Simultaneous DTP, Hepatitis B, and Hib Immunization

Jung-Hwan Park*^{1,2}, In-Jeong Choi², Seojin Byun¹, Seung-Ki Baek², ¹Gachon University, Republic of Korea, ²QuadMedicine Inc, Republic of Korea

[P3.85]

Evaluating Online Vaccination Imagery: How Misleading Photos Could Impact Safety

Xinyi Zhang¹, Mark Davis¹, Diana Vlasenko^{2,3}, Jo Hickman^{2,4}, Jim Buttery^{2,3,5,6}, ¹School of Culture and Communication, Faculty of Arts, The University of Melbourne, Australia, ²Centre for Health Analytics, Melbourne Children's Campus, Melbourne, Victoria, Australia, ³SAEFVIC, Murdoch Children's Research Institute, Melbourne, Victoria, Australia, ⁴Monash Health, Melbourne, Victoria, Australia, ⁵Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia, ⁶Royal Children's Hospital, Melbourne, Victoria, Australia

[P3.86]

Virtual prenatal care and influenza vaccination during pregnancy: a multi-state analysis of U.S. mothers, 2020-2021

Don Willis¹, Cari Bogulski¹, Clare Brown², James Selig¹, Ji Li¹, Nirvana Manning², Donya Watson³, Constance Chapman⁴, Pearl McElfish¹, ¹University of Arkansas for Medical Sciences - Northwest Regional Campus, USA, ²University of Arkansas for Medical Sciences, USA, ³University of Arkansas for Medical Sciences - South Regional Campus, USA, ⁴Mainline Health Systems Inc, USA

[P3.87]

Challenges in childhood vaccinations acceptance in the Post Covid-19 era

Chen Stein-Zamir*, Hebrew University of Jerusalem Faculty of Medicine, Israel

[P3.88]

The role of TBK1 in B cells in the maintenance of chronic germinal centers in Peyer's Patches

Mariana Silva Almeida¹, Niloufar Kavian Tessler¹, Jalal Alshaweesh¹, Rashmi Rekha Dash¹, Reiko Shinkura², Takeshi Inoue³, Jun Kunisawa⁴, Ken J Ishii⁵, Cevayir Coban¹, ¹Division of Malaria Immunology, Department of Microbiology and Immunology, The Institute of Medical Science (IMSUT), The University of Tokyo, Japan, ²Laboratory of Immunology and Infection Control, Research Division for Quantitative Life Sciences (IQB), Japan, ³Department of Molecular Systems Immunology, The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), Japan, ⁴Laboratory of Vaccine Materials and Laboratory of Gut Environmental System, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Japan, ⁵Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science (IMSUT), The University of Tokyo, Japan

[P3.89]

Systemic, operational and infrastructural challenges cause vaccine stock-outs in South Africa

Johanna Meyer^{1,2}, Mncengeli Sibanda^{1,2}, Zeenat Ismail^{1,2}, Marione Schönfeldt³, Mercy Kamupira⁴, Sufang Guo⁴, Rosemary Burnett^{1,2}, ¹Sefako Makgatho Health Sciences University, South Africa, ²South African Vaccination and Immunisation Centre, Sefako Makgatho Health Sciences University, South Africa, ³Republic of South Africa Department of Health, South Africa, ⁴United Nations Children's Fund (UNICEF), Pretoria, South Africa

[P3.90]

Computational identification and evaluation of novel SGLT-2 inhibitors with antidiabetic and antioxidant potential

Kunika Saini*, Smriti Sharma, University of Delhi, India

[P3.91]

Evaluating the effect of midstream supply chain disruptions on the distribution of polio vaccines in Indonesia

Erlly Sintya^{1,2,3}, Farshid Babaei¹, David B. Robins¹, Solomon F. Brown¹, ¹The University of Sheffield Department of Chemical and Biological Engineering, UK, ²University of Warmadewa Faculty of Health and Medicine, Indonesia, ³Center for Climate Change, Indonesia

[P3.92]

CpG/Tat nanoring-adjuvanted intranasal vaccination for lung tissue-resident memory cd8⁺ t cell induction and enhanced immune protection

Buse Duru Aras^{1,2}, İrem Evcilli¹, Dicle Çalışkan^{1,3}, Müge Özkan¹, Muzaffer Yıldırım¹, Mayda Gürsel¹, Bilgi Güngör^{1,2}, ¹Izmir Biomedicine and Genome Center, Turkey, ²Dokuz Eylül University, Izmir International Biomedicine and Genome Institute, Molecular Biology and Genetics Department, Izmir, Turkey, ³Dokuz Eylül University, Izmir International Biomedicine and Genome Institute, Molecular Biology and Genetics Department, Izmir, TÜRKİYE, Turkey

[P3.93]

Development and Evaluation of a *P. multocida* A-M. haemolytica A6-rLkt Combined Vaccine for Enhanced Control of Bovine Respiratory Disease Complex

Ruicheng Yu*, Yingyu Chen, Aizhen Guo, Huazhong Agricultural University, China

[P3.94]

Exploring the Potential of Avian Paramyxovirus Type 14 as a Viral Vector

Jae-Eun Lee*, Jiwon Kim, Eunbin Lee, Young Ki Choi, Sungsu Youk, *Microbiology Laboratory, College of Medicine, Chungbuk National University, Republic of Korea*

[P3.95]

Development of Vero cell-derived master donor viruses for emergency production of influenza A and B vaccines

Chun-Hsiang Chuang*, *National Tsing Hua University Institute of Molecular and Cellular Biology, Taiwan, National Health Research Institutes, Taiwan*

[P3.96]

Site-specific Glycan Masking of Hemagglutinin Head Domain Induces Broadly Neutralizing Antibodies Against H7N9 Viruses

Tsai-Chuan Weng¹, Asmaul Husna^{1,2}, Yu-Chieh Cheng¹, Min-Han Lin¹, Min-Shi Lee¹, Wang-Chou Sung*¹, ¹*National Health Research Institutes, Taiwan, 2**National Tsing-Hua University, Taiwan*

[P3.97]

A new VLP-based vaccine protects hares against EBHS

Giulio Severi*¹, Lucia Anzalone¹, Laura Madeo¹, Anna Serroni², Claudia Colabella³, Antonella Di Paolo¹, Piermario Mangili¹, Elisabetta Manuali¹, Andrea Felici¹, Monica Cagiola¹, Antonio Lavazza⁴, Lorenzo Capucci⁴, Giovanni Pezzotti¹, Antonio De Giuseppe¹, ¹*Zooprophylactic Institute of Marche and Umbria, Italy, 2**Zooprophylactic Institute of Abruzzo and Molise Giuseppe Caporale, Italy, 3**Analysis Laboratory "S. Matteo Degli Infermi Hospital", USL Umbria 2, Italy, 4**Zooprophylactic Institute of Lombardia and Emilia-Romagna Bruno Ubertini, Italy*

[P3.98]

A dipping bivalent inactivated novel autogenous vaccine prevent *Aeromonas salmonicida* e *Yersinia ruckeri* infection in rainbow trout

Giulio Severi*¹, Martina Pellegrini¹, Giulia Vita¹, Silvia Cardaioli¹, Rosario Liberti¹, Antonella Di Paolo¹, Francesco Agnetti¹, Monica Cagiola¹, Vincenzo Caputo¹, Ciro Castellano², ¹*Zooprophylactic Institute of Marche and Umbria, Italy, 2**Erede Rossi Silvio Farm Fish Health Manager, Italy*

[P3.99]

Autogenous vaccines and good manufacturing practice (GMP): a global threat or an opportunity?

Giulio Severi*, Martina Pellegrini, Giulia Vita, Rosario Liberti, Lucia Anzalone, Antonella Di Paolo, Giovanni Curina, Antonio De Giuseppe, Monica Cagiola, *Zooprophylactic Institute of Marche and Umbria, Italy*

[P3.100]

Intranasal vaccination with probiotic *Escherichia coli* membrane vesicle chimera elicits potent and long-lasting mucosal immunity

Ryoma Nakao*¹, Soichiro Kimura^{2,3}, Kimihiro Abe^{1,4}, Takehiro Yamaguchi¹, Eisuke Kuroda^{5,6,7}, Shigeto Kuroda^{5,8}, Kazuhiro Tateda³, Yukino Ohki⁹, Naoki Narisawa⁹, Makoto Ohnishi¹, Yukihiro Akeda¹, ¹*Department of Bacteriology I, National Institute of Infectious Diseases, Japan Institute for Health Security (JIHS), Japan, 2**Division of Infection Prevention and Control, Faculty of Pharmaceutical Sciences, Shonan University of Medical Sciences, Japan, 3**Department of Microbiology and Infectious Diseases, Faculty of Medicine, Toho University School of Medicine, Japan, 4**Research Center for Vaccine Development, National Institute of Infectious Diseases, Japan Institute for Health Security (JIHS), Japan, 5**Department of Transformative Analysis for Human Specimen, Osaka University Graduate School of Medicine, Japan, 6**Division of Fostering Required Medical Human Resources, Center for Infectious Disease Education and Research (CiDER), Osaka University, Japan, 7**Division of Infection Control and Prevention, Osaka University Hospital, Jamaica, 8**Division of Infection Control and Prevention, Osaka University Hospital, Japan, 9**Department of Food Bioscience and Biotechnology, College of Bioresource Science, Nihon University, Japan*

[P3.101]

Safety and vaccine efficacy of outer membrane vesicles of three isogenic lipid A mutants of probiotic *Escherichia coli*

Ryoma Nakao¹, Nozomu Obana², Ryunosuke Tominaga*^{1,3}, Ryoko Sato⁴, Chihiro Tokuda⁴, Kazuyoshi Kawahara⁵, ¹*Japan Institute for Health Security, Japan, 2**University of Tsukuba, Japan, 3**Tokyo University of Technology, Japan, 4**MiCAN Technologies Inc., Japan, 5**Kanto Gakuin University, Japan*

[P3.102]

Institutional Disparities in Newborn Hepatitis B Vaccine Refusal: Racial and Socioeconomic Inequities Across Hospitals in Washington, DC (2017–2023)

Y. Tony Yang*, *The George Washington University, USA*

[P3.103]

Strategies, barriers and facilitators for healthcare professionals to recommend HPV vaccination: A systematic review

Yihan Fu*, Yinqi He, Zhitao Wang, Jing Sun, *Chinese Academy of Medical Sciences and Peking Union Medical College, China*

[P3.104]

Single-particle profiling of immune cell-derived extracellular vesicles in vivo with potential implications for immune modulation

Tomoya Hayashi^{1,2,3}, Shuntaro Shimizu^{1,2,3,4}, Kouji Kobiyama^{1,2,3}, Hideo Negishi^{1,2,3}, Burcu Temizoz^{1,2,3}, Ken Ishii^{1,2,3}, *¹Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo (IMSUT), Japan, ²International Vaccine Design Center, IMSUT, Japan, ³The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), Japan, ⁴Department of Chemistry, Chemical Engineering & Life Science, Yokohama National University, Japan*